


This document is confidential and is proprietary to the American Chemical Society and its authors. Do not copy or disclose without written permission. If you have received this item in error, notify the sender and delete all copies.

Polysilicon Microchips Functionalized with Bipyridinium-based Cyclophanes for a Highly Efficient Cytotoxicity in Cancerous Cells

Journal:	ACS Nano
Manuscript ID	nn-2021-08090a.R2
Manuscript Type:	Article
Date Submitted by the Author:	n/a
Complete List of Authors:	Limón, David; Northwestern University, Department of Chemistry Hornick, Jessica; Northwestern University, Molecular Biosciences Cai, Kang; Northwestern University, Department of Chemistry Beldjoudi, Yassine; Northwestern University, Department of Chemistry Duch, Marta; Instituto de Microelectrónica de Barcelona Plaza, Jose A; Instituto de Microelectrónica de Barcelona, Micro and Nanosystems Pérez-García, Lluïsa; Universitat de Barcelona, Pharmacology and Therapeutical Chemistry, Faculty of Pharmacy and Food Science Stoddart, J. Fraser; Northwestern University, Department of Chemistry

SCHOLARONE™
Manuscripts



Self-renewing bipyridinium-functionalized microparticles internalize in cancerous cells and induce lipid peroxidation in cell membranes, leading to a highly efficient cytotoxicity.

Polysilicon Microchips Functionalized with Bipyridinium-based Cyclophanes for a Highly Efficient Cytotoxicity in Cancerous Cells

David Limón^{a,b,c,*}, Jessica E. Hornick^d, Kang Cai^a, Yassine Beldjoudi^a, Marta Duch^e, José A. Plaza^e, Lluïsa Pérez-García^{b,c}, J. Fraser Stoddart^{a,f,g,h,*}

^aDepartment of Chemistry, Northwestern University, 60208, Evanston, Illinois, United States.

^bDepartment of Pharmacology, Toxicology, and Therapeutic Chemistry, Faculty of Pharmacy and Food Science, University of Barcelona, 08028, Barcelona, Spain.

^cInstitute of Nanoscience and Nanotechnology, University of Barcelona (IN2UB), 08028, Barcelona, Spain.

^dDepartment of Molecular Biosciences, Northwestern University, 60208, Evanston, Illinois, United States.

^eInstitute of Microelectronics of Barcelona IMB-CNM (CSIC), 08193, Barcelona, Spain.

^fSchool of Chemistry, University of New South Wales, Kensington NSW 2033, Sydney, Australia

^gStoddart Institute of Molecular Science, Department of Chemistry, Zhejiang University, 311418, Hangzhou, China

^hZJU-Hangzhou Global Scientific and Technological Innovation Center, 311215, Hangzhou, China

Email: davidlimon@ub.edu; stoddart@northwestern.edu

Abstract

The use of micrometric-sized vehicles could greatly improve selectivity of cytotoxic compounds as their lack of self-diffusion could maximize their retention in tissues. We have used polysilicon microparticles (**SiμP**) to conjugate bipyridinium-based compounds, able to induce cytotoxicity under regular intracellular conditions. Homogeneous functionalization in suspension was achieved, where the open chain structure exhibits a more dense packing than cyclic analogues. The microparticles internalized induce high *cytotoxicity per particle* in cancerous HeLa cells, and the less densely packed functionalization using cyclophanes promote higher *cytotoxicity per bipy* than with open chain analogues. The self-renewing ability of the particles and their proximity to cell membranes may account for increased lipid peroxidation, achieving toxicity at much lower concentrations than in solution, and proving these microchips as a promising platform for inducing highly efficient cytotoxicity in cancerous cells.

Keywords: polysilicon microparticles, bipyridinium, HeLa cells, cancer, lipid peroxidation, cytotoxicity.

Highly cytotoxic compounds are essential in cancer chemotherapy. Chemotherapeutic drugs used in the clinic typically inhibit mitosis in cancerous cells, by either binding to DNA (*e.g.* doxorubicin),¹ inhibiting the production of DNA base pairs (*e.g.* methotrexate),² inhibiting topoisomerase enzyme which untangles DNA for its replication (*e.g.* topotecan),³ binding to protein kinase receptors (*e.g.* imatinib),⁴ or inhibiting the functional assembly of microtubules (*e.g.* paclitaxel),⁵ all of which result in cell death. After oral or intravenous administration, however, their circulation in blood, extravasation, further diffusion across healthy tissues, and lack of selectivity for cancerous cells leads to cytotoxicity in healthy tissues as well, inducing side effects in patients.⁶⁻⁹

Some strategies for focalizing the cytotoxic effects within tumors and reducing side effects have been developed. Photodynamic therapy (PDT), which relies on the generation of reactive oxygen species (ROS) in cells upon

1
2
3 41 irradiation of a previously administered photosensitizer, permits the focalization of the irradiation, but the
4 42 distribution of the photosensitizers across other tissues lead to side effects after sun exposure.¹⁰
5

6 43 Intratumoral chemotherapy (ITC), another strategy that has recently gained interest, relies on the direct injection
7 44 of chemotherapeutic drugs within a tumor. It permits controlling the initial amount and localization of the drug
8 45 administered, assisted by relatively simple techniques (*e.g.* ultrasound imaging). However, the injected drugs can
9 46 also diffuse to surrounding tissues and be reabsorbed into the systemic circulation.¹⁰

11 47 A widely used strategy is the encapsulation of chemotherapeutic drugs into nanocarriers (*e.g.* vesicles, liposomes,
12 48 or nanoparticles). According to the Enhanced Permeability and Retention (EPR) effect, the larger size of
13 49 nanocarriers as compared to free drugs in solution promotes higher extravasation and retention in solid tumors,
14 50 where the vasculature is leaky and the lymphatic vessels constricted.¹¹⁻¹⁴ Nonetheless, the efficiency of the EPR
15 51 effect to target tumors has been recently questioned because, as although a higher extravasation can occur in the
16 52 tumor area, the densely packed cancerous cells may keep the nanocarriers in the periphery of the tumor,¹⁵ with
17 53 only negligible amounts reaching the cells.^{16,17} Another beneficial aspect of nanocarriers is their decreased
18 54 Brownian motion as compared to molecules in solution, according to the Stokes-Einstein equation.¹⁸ Therefore,
19 55 once the nanocarriers are located within a tumor, they show decreased diffusion to surrounding healthy tissues.
20 56 Recent studies demonstrate that the dense cell packing reduces the mobility of the particles in the medium much
21 57 more than predicted by theory, where the self-diffusion coefficient across cells is exponentially decreased by the
22 58 square of the radius of the particles.¹⁹ Many aspects influence this decreased diffusion, including a higher contact
23 59 area with cell membranes,²⁰ hydrophobicity of the cell membranes,²¹ cell uptake,²⁰ positive charges on the particles
24 60 surface,²² or higher rates of sedimentation.²³ However, the self-diffusion is not negligible; in fact, nanoparticles
25 61 can even diffuse through the tissues with barrier function, for example, nanoparticles can be used as transdermal
26 62 delivery systems.^{15,24-27} As well, chemotherapeutic drugs are typically nanoencapsulated by non-covalent bonds,
27 63 such as electrostatic or hydrophobic interactions, which could result in leakage of the drugs before reaching the
28 64 tumor, or their diffusion from the tumor to surrounding tissues. Examples of this phenomenon include
29 65 doxorubicin-containing liposomes (Doxil®), which commonly induce dermatitis, flushing, and shortness of
30 66 breath, and paclitaxel-containing liposomes (Abraxane®), which increase the cost of treatment as higher doses
31 67 are required for a similar efficacy.¹⁴

32 68 Instead, the use of micrometric-sized particles would provide considerable advantages, such as their negligible
33 69 self-diffusion coefficients in suspension and especially in tissues,^{18,19,28} improving their retention in the site of
34 70 administration along time. Silicon microparticles can be fabricated using photolithographic techniques or
35 71 milling,^{29,30} and due to their biocompatibility they have been used for drug delivery applications,^{31,32} but
36 72 encapsulating the drugs non-covalently in the nanoporous material. We have shown that micrometric-sized
37 73 particles of different materials, shapes, and sizes can be fabricated using microelectronic-based techniques,³³
38 74 achieving extremely low polydispersity as compared to microparticles chemically synthesized. They can interact
39 75 with living cells, working as intracellular pH sensors,³⁴ as micrometric tags for real-time tracking of cells,³⁵⁻³⁷ or
40 76 other applications. Among the different types of particles, hexahedral polysilicon (3 x 3 x 0.5 μm) microparticles
41 77 (**SipP**) represent a simple platform for immobilization of compounds with biomedical interest, as they can be
42 78 easily observed even under brightfield microscopy, are relatively innocuous, and can be internalized into cells
43 79 without reaching the nucleus.³⁷⁻⁴¹ Also, the compounds conjugated to the particles can maintain their
44 80 physicochemical properties; for example, porphyrins immobilized onto **SipP** show fluorescence equivalent to that
45 81 in solution and can generate singlet oxygen in PDT.⁴²

46 82 On the other hand, bipyridinium-derived compounds have wide interest for their ability to work as components
47 83 of molecular machines, as π -electron-deficient bipyridinium moieties interact with π -electron-rich donor
48 84 compounds, producing a host-guest interaction that can be controlled under external stimuli. The range of
49 85 different architectures of bipyridinium compounds permits the template-guided synthesis of mechanically
50
51
52
53
54
55
56
57
58
59
60

1
2
3 86 interlocked molecules such as catenanes, rotaxanes, or pseudorotaxanes, which can be used as molecular
4 87 switches,^{43,44} artificial molecular muscles,⁴⁵ among others. Moreover, bipyridinium compounds show interesting
5 88 optical properties that may be useful in for imaging applications.⁴⁶⁻⁴⁸ However, the use of compounds bearing
6 89 bipyridinium moieties for biomedical applications remains limited because of their intrinsic toxicity. Instead, the
7 90 1,1'-dimethyl-4,4'-dipyridinium dication, commonly known as methyl viologen (**1**) (Figure 1, A), has been used
8 91 extensively as an herbicide.⁴⁹ The cytotoxicity of bipyridinium moieties is due to their easy reduction to the radical
9 92 cation entity under mild intracellular conditions, such as the presence of NADPH catalyzed by NADPH-cytochrome
10 93 c reductase. In presence of dissolved oxygen, the radical cation is oxidized again regenerating the bipyridinium
11 94 moiety. Upon oxidation, superoxide radical anion is formed and transformed into other oxygen radicals, which
12 95 attack unsaturated lipids of the cell membrane triggering lipid peroxidation, a radical chain reaction that
13 96 eventually induces increased membrane fluidity, membrane integrity loss, and cell death.⁴⁹⁻⁵¹ Although this
14 97 toxicity is also non-selective for cancerous cells, it could be revisited for biomedical purposes such as the treatment
15 98 of cancer, as it is independent on nucleus internalization, making it more efficient than other chemotherapeutic
16 99 drugs. The cytotoxic potential of bipyridinium on cancerous cells has been studied in solution, observing that the
17 100 length of the alkyl chain substituents has an important influence on their cytotoxicity;⁵² nonetheless, strategies for
18 101 focalizing their cytotoxic effects still need to be found. Bipyridinium-derived compounds have been conjugated
19 102 onto nanoparticles, mainly for electrochemical sensing,^{53,54} or as gatekeepers of drug-loaded systems,^{55,56} but not
20 103 for this purpose.

21 104 Therefore, **SiμP** could be functionalized with compounds bearing bipyridinium moieties, as a platform that could
22 105 potentially improve the spatial focalization of the cytotoxic effects in tissues. The microparticles could be directly
23 106 injected with control over the number and location of particles dosed. The cytotoxic effects could be focalized due
24 107 to the negligible diffusion of the microparticles and the covalent conjugation of the drugs that prevents their
25 108 leakage and further diffusion in solution. For this reason, compounds **1**, **2**, and **3** (Figure 1, A) were selected for
26 109 having bipyridinium moieties in different number and arrangement, and a strategy was designed to immobilize
27 110 them onto **SiμP**. The functionalization was first optimized on macroscopic wafers patterned with polysilicon
28 111 microparticles (Figure 1, B), with the purpose of controlling the functionalization along different stages using
29 112 parameters such as the hydrophobicity, the fluorescence, or the atomic content. Once the functionalization
30 113 protocol was optimized, the protocol was adapted to functionalize the microparticles in suspension (Figure 1, C).
31 114 The ability of the unfunctionalized and functionalized particles to be internalized in cancerous Hela cells was
32 115 observed, and their ability to induce cell death was evaluated using confocal fluorescence microscopy, showing the
33 116 great potential of **SiμP** functionalized with bipyridinium-containing compounds for inducing highly efficient
34 117 cytotoxic effects in cancerous cells.

35 118




Figure 1. (A) Chemical structures of compounds immobilized (**1**, **2**, and **3**). Compound **1** bears one bipyridinium moiety (open chain), whereas compounds **2** and **3** bear two bipyridinium moieties (cyclic structure). Compound **3** bears bipyridinium moieties extended by *p*-phenylene spacers. (B) SEM images of polysilicon microparticles fabricated onto a silicon oxide wafer. (C) SEM images of polysilicon microparticles once released in suspension (**SiμP**). Scale bar represents 2 μm .

Results

Design of the system

With the aim of designing a system that could improve the localization of cytotoxic effects in chemotherapy, polysilicon microparticles (**SiμP**) were chosen for their biocompatibility and their potential to be chemically functionalized with cytotoxic compounds, their negligible diffusion, and their fast sedimentation. According to their easy internalization and localization within the cytoplasm, the compounds conjugated should display cytotoxicity through mechanisms different than the direct binding to DNA, as is the case of ROS generation. To this end, bipyridinium-containing compounds are ideal because they can be reversibly reduced under mild biological conditions and generate ROS.^{50,51} Moreover, the overall number and arrangement of bipyridinium (bipy) units in the system could have an influence on the efficacy. For this reason, compounds **1**, **2**, and **3** (Figure 1, A) were selected to be conjugated to the **SiμP**, as **1** has been widely used and bears one bipy unit, whereas **2** and **3** both have two bipy units each in a macrocyclic structure, permitting a comparison between the macrocyclic *versus* the open-chain structures. In addition, **3** bears the bipyridinium moieties extended by *p*-phenylene groups, permitting a comparison between the extended *versus* the non-extended structures. Compound **2**, a structural analog of the widely-known *bluebox*,⁴³ was designed to incorporate an azide terminal group, used for its conjugation onto the particles, whereas compound **3** bears carboxylic acid groups for its conjugation.

The ability of the three selected compounds (**1**, **2**, and **3**) to be reversibly reduced in solution under mild conditions was confirmed using Differential Pulse Voltammetry (DPV) (Figure 2, A).




Figure 2. A) Differential Pulse Voltammograms of compounds **1** (top), **2** (middle), and **3** (bottom) in DMF solution (1 mg per 3 mL). B) Schematic representation of **SiμP** fabrication. (1) Silicon wafer. (2) A silicon oxide layer is grown as sacrificial layer. (3) A polysilicon layer is deposited as structural layer. (4-5) A photoresist layer is spun and exposed to light. (6) Photoresist after developer. (7) Dry etching of the exposed polysilicon layer. (8) Photoresist removal. (9) Sacrificial etching of the silicon oxide layer to release the chips.


The voltammogram for **1** (top) shows two oxidation-reduction peaks at -0.33 and -0.71 V, corresponding to two possible redox transitions, the first one occurring from the dicationic form to the radical cation entity, and the second one occurring from the radical cation to the neutral entity. As the structure of **2** (middle) contains two equivalent bipyridinium moieties, also two peaks are observed in its voltammogram at -0.25 V and -0.67 V, corresponding to the same redox transitions. In contrast, **3** (bottom) showed two peaks that are partially overlapped, occurring at -0.60 and -0.88 V, respectively. The results also show that the compound presenting the first redox transition (to the radical cation) at the potential closest to zero is **2** (-0.25 V), occurring at slightly higher values than that of **1** (-0.3 V), and showing values very similar to those of its isomer *bluebox*,⁵⁷ whereas the first reduction in **3** occurs at a more negative potential (-0.60 V), indicating that the extended bipyridinium moieties lead to a more difficult transition to the radical cation moiety. Although the use of DMF might lead to small differences in the redox potential as compared to biological media, the ability of compound **1** to be intracellularly reduced by NADPH catalyzed by NADPH-cytochrome c dehydrogenase, and re-oxidized in presence of oxygen is well documented,^{50,51} for which the comparable potentials between the three compounds in DMF indicate that all of them can be intracellularly reduced. Nonetheless, although this finding could initially predict that compounds **2** and **1** could induce higher ROS generation in cells as compared to **3** when administered in solution, the covalent immobilization of these compounds on the surface of the microparticles could influence their redox transitions and thus their ability to generate ROS.

Polysilicon microparticles (**SiμP**) were fabricated as shown in Figure 1, B.^{41,42} Briefly, a $1\text{-}\mu\text{m}$ thick *p*-type silicon wafer with a 100-mm diameter was used as a starting substrate (1). A silicon oxide layer was grown as a sacrificial layer (2). Next, a 500 nm polysilicon layer was deposited on top as a structural layer (3). By using microelectronic fabrication techniques as lithography and dry etching, the **SiμP** were patterned (4-8). The patterned particles have a cuboid shape with lateral dimensions defined by the photolithographic processes and their thickness defined by the thickness of the previously deposited structural layer ($3 \times 3 \times 0.5 \mu\text{m}^3$). Lastly, the particles were released from the substrate by a sacrificial etching of the sacrificial silicon oxide layer using a vapor of 50 % hydrogen fluoride (9), and then suspended and collected in ethanol in Eppendorf tubes for their posterior chemical functionalization.

1
2
3 173 The functionalization was first optimized using macroscopic silicon oxide wafers with the polysilicon
4 174 microparticles on top (Figure 1, B; Figure 2, B 8), as it permits an easier manipulation of the material as well as
5 175 the characterization of the properties of the surface such as hydrophobicity, fluorescence, or elemental
6 176 composition. Once the protocol is optimized, the reaction setup can be adapted to functionalize the polysilicon
7 177 microparticles in suspension. Therefore, the chemical strategy was designed to overcome the future limitations of
8 178 microparticle functionalization, such as the limited range of temperatures for using plastic microtubes, or the use
9 179 of solvents that permit suspending the microparticles under vortex but also sedimenting them under
10 180 centrifugation during washes. In general, **Si μ P** are more easily suspended in water than in organic solvents (*e.g.*
11 181 acetone, ethanol, isopropanol), making their sedimentation difficult and leading to considerable particle losses.
12 182 For this reason, water was avoided whenever possible along the functionalization.

13
14
15 183 Figure 3 (A-C) shows the optimized strategy for obtaining silicon wafers functionalized with the three different
16 184 bipyridinium-containing compounds, **1** (**Si-1**) (A), **2** (**Si-2**) (B), or **3** (**Si-3**) (C), where the different
17 185 functionalization steps followed are numbered under each structure (*functionalization stages*) for the purpose of
18 186 clarity. According to this strategy, the counter anions of the bipyridinium moieties formed upon conjugation of
19 187 the compounds are hexafluorophosphate anions in the case of **Si-2** and **Si-3**, and bromide and iodide in the case
20 188 of **Si-1**. Although it is well known that the counter anion has an influence on the solubility of bipyridinium
21 189 compounds and may affect their reduction potential, the immersion of the functionalized microparticles in a
22 190 biological medium would likely result in the exchange of the counter anions for those present in the medium, such
23 191 as phosphate or chloride, and for which the effect of the counter anion on the efficacy could be negligible. The
24 192 three different self-assembled monolayers (SAMs) were designed to have similar thicknesses (the total length of
25 193 the linker-bipyridinium compound is similar), for which the properties of the material and of the microparticles,
26 194 as well as their efficacy, could be related to the number and arrangement of bipyridinium units. MM2
27 195 minimizations of the functionalized moieties in each type of particle were performed (See Supporting Information
28 196 “MM2 calculations”), and ideal representations of the respective SAMs formed are shown in Figure 3 (D, E, and F,
29 197 respectively). As it can be seen, the open chain structure of the moieties conjugated in **Si-1** permits a more densely
30 198 packed SAM as compared to the cyclic structures in **Si-2** and **Si-3**, meaning that a higher number of molecules
31 199 of **1** could be conjugated on the surface.

32
33
34
35 200
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



201
202 **Figure 3.** (A-C) Functionalization strategy followed for obtaining silicon wafers functionalized with (A) **1** (**Si-1**), (B) **2** (**Si-2**), or (C) **3** (**Si-**
203 **3**). Functionalization stages are displayed under each structure for the purpose of clarity. (D-F) Ideal models of functionalized silicon wafers
204 (D) **Si-1** (E) **Si-2**, and (F) **Si-3** according to MM2 minimizations.

205 **Functionalization of silicon wafers**

206 Wafers of ≈ 0.25 cm² were first washed with water and ethanol and were dried with a stream of nitrogen (stage
207 1). Subsequently, the wafers were activated using acid treatment followed by basic treatment (stage 2) to provide

the surface with hydroxyl groups. After activation, a suitable linker bearing a silane moiety was covalently attached to the hydroxyl groups on the surface (stage 3). This linker therefore acts as a spacer and provides a suitable functional group for further attachment of the bipyridinium compounds. Functionalization of wafer surfaces with methyl viologen (**Si-1**) (Figure 3, A), consists of the use of 11-bromoundecyl trichlorosilane as the linker (stage 3), which provides the surface with an alkyl bromide group, the subsequent conjugation of the 4,4'-bipyridine (stage 4), and the final installation of a methyl group using methyl iodide (stage 5). The functionalization with **2** (**Si-2**) is carried out by using APTES as the linker (stage 3), the conjugation of propargyl bromide as a secondary linker (stage 4), which provides the surface with a terminal alkyne group, and the final conjugation of compound **2** through a Cu(I)-catalyzed azide-alkyne cycloaddition (stage 5). Likewise, the functionalization with **3** (**Si-3**) entails the use of APTES as the linker (stage 3) providing the surface with terminal amino groups, and the final conjugation of the **3** using NHS/EDC coupling (stage 5). All reactions were performed at room temperature. After each reaction, the wafers were thoroughly washed with the solvent used in the reaction to remove excess reactants, then with acetone, and were finally dried with a stream of nitrogen before the next stage.

The functionalization was first assessed by performing contact angle measurements on the wafers, to determine their hydrophobicity upon each functionalization stage, as depicted in the Supporting Information (Table S 1). Silicon wafers without any functionalization (stage 1) show a contact angle of $46.2 \pm 5.2^\circ$, similar to previously reported results.^{36,58} In contrast, the activation of the wafers performed by acid and basic treatment (stage 2) led to a significant decrease in the contact angle ($23.5 \pm 4.3^\circ$), which is in accordance with the presence of hydroxyl groups on the surface. The further addition of the linker (stage 3) led in all cases to an increase in the contact angle, as the surface becomes more hydrophobic due to the presence of a hydrocarbon chain. The surface showing the highest contact angle in stage 3 is **Si-1** ($96.4 \pm 2.0^\circ$), where the linker incorporates the longest alkyl chain (11 carbons), while the contact angle obtained when the linker is a 3-carbon chain and a final amino group (**Si-2** or **Si-3**) is $57.9 \pm 9.5^\circ$. Furthermore, the conjugation of a secondary linker (stage 4) resulted in a decrease in the contact angle. In the case of **Si-1** wafers, the conjugation of 4,4'-bipyridine in this stage implies the formation of one positive charge upon formation of one pyridinium moiety, leading to a more hydrophilic surface. Finally, in the three wafers studied (**Si-1**, **Si-2** and **Si-3**), stage 5 resulted in a further decrease in the contact angle as compared to the previous stage, in accordance with the positive charges of bipyridinium moieties that make the surface more hydrophilic. The lowest contact values observed correspond to **Si-2** and **Si-3** ($22.7 \pm 5.2^\circ$ and $25.6 \pm 3.4^\circ$, respectively), where each conjugated compound have four positive charges, as opposed to **Si-1** having two positive charges. These results suggest successful functionalization along the different functionalization stages.

Quantification and homogeneity of the functionalization

The functionalization was assessed and quantified by studying the atomic content of the wafers along the different functionalization stages using XPS. Binding energy plots of the different elements analyzed in the different wafers (**Si-1**, **Si-2**, **Si-3**) can be found in the Supporting Information (Figure S 1 to Figure S 3, respectively). The atomic content of C1s, N1s, Br3d, I3d, P2p, and/or F1s relative to Si2p was calculated by dividing the atomic content of each element by the atomic content of Si2p. The relative atomic content calculated along the different functionalization stages can be seen in the Supporting Information (Table S 2 - Table S 4) and is shown in Figure 4.




Figure 4. Atomic content relative to Si_{2p} along the different stages of functionalization (1 to 5) of silicon wafers: A) Si-1, B) Si-2, C) Si-3.

The Si-1 wafers (A) show subsequent increases in carbon content (with respect to Si_{2p}) along the different stages, in accordance with the increasing carbon chain length on the surface. A drastic increase is especially seen in stage 3 (from 22 % to 260 % with respect to Si_{2p}), corresponding to the conjugation of the 11-carbon linker. Likewise, a significant increase in bromine content (0 % to 17 %) is seen in stage 3, as it is covalently attached on the surface, in nitrogen content in stage 4 (from 8 % to 20 %), corresponding to the conjugation of 4,4'-bipyridine, and in iodine content in stage 5 (from 1 % to 10 %), showing the presence of the counter anion. Similarly, the functionalization of Si-2 (Figure 4, B), shows a gradual increase in carbon content from stage 3, with a significant increase in stage 5 (from 52 % to 197 %), where the functionalization involves the highest number of carbon atoms attached. The gradual increase in nitrogen content along the stages also suggests a successful functionalization, especially considering that, during stage 5 (from 10 % to 33 %), the highest number of nitrogen atoms is functionalized on the surface. Furthermore, fluorine can be detected in stage 5 (from 2 % to 5 %), in accordance with the presence of PF₆⁻ counter anions. Likewise, Si-3 wafers (Figure 4, C) show the presence of fluorine in stage 5 (from 2 % to 8 %) due to PF₆⁻ anions, while a gradual increase in carbon content was observed in stages 3 and 5.

The identity of the moieties functionalized on the surface was confirmed by calculating the ratio of N/C atomic content measured for each surface, as both are covalently bonded elements, and this ratio was compared to the theoretical ratio according to the chemical structure of each moiety (Table 1). The measured N/C ratios were similar to the theoretical N/C ratios for Si-1 (0.06 vs 0.09, respectively), Si-2 (0.17 vs. 0.18), and Si-3 (0.13 vs. 0.09), suggesting functionalization in all cases.

Table 1. Estimation of surface coverage [%] of functionalized silicon wafers (Si-1, Si-2, and Si-3) based on XPS analysis. The similarity of the measured N/C ratios to the theoretical N/C ratios suggests the correct identity of the conjugated moieties.

	Si-1	Si-2	Si-3
Measured N1s content relative to Si _{2p} [%]	17.6	32.6	12.8
Measured C1s content relative to Si _{2p} [%]	311.3	197.4	100.1
Max theoretical C1s content relative to Si _{2p} [%]	550	1100	1325
Surface coverage [%]	57	18	8
Measured N/C ratio	0.06	0.17	0.13
Theoretical N/C ratio	0.09	0.18	0.09
Estimated Si atoms functionalized per nm ²	41	13	5
Estimated moieties conjugated per nm ²	14	4	2
Estimated moieties conjugated per microparticle	3.25 × 10 ⁸	1.03 × 10 ⁸	4.34 × 10 ⁷

1
2
3 272 In order to estimate the proportion of silicon atoms functionalized (surface coverage), the maximum theoretical
4 273 atomic content (relative to Si₂p) of each element was calculated assuming all the silicon atoms on the surface are
5 274 functionalized forming a monolayer, and the measured atomic content from each sample was compared to the
6 275 theoretical content. Also, according to the atomic radius of polycrystalline silicon (0.118 nm) (ca. 72 Si atoms per
7 276 nm²), the number of moieties functionalized per nm² was estimated (Table 1). According to the content of C_{1s},
8 277 around 57 % of silicon atoms on the surface of **Si-1** wafers are functionalized (57 % surface coverage), meaning
9 278 that up to 14 moieties of **1** could be immobilized per nm². In contrast, **Si-2** wafers show around 18 % surface
10 279 coverage, meaning that up to 4 moieties of **2** could be conjugated per nm², and **Si-3** show around 8 % of surface
11 280 coverage, meaning that up to 2 moieties of **3** could be conjugated per nm². These differences in surface coverage
12 281 can be thus related to the structural differences, where the open chain structure in **Si-1** could form a tighter SAM
13 282 containing a larger number of moieties, as observed in the representation based on MM2 minimizations (Figure
14 283 3, D), whereas the bigger macrocyclic structure of **Si-3** results in a lower number of moieties per surface area
15 284 (Figure 3, F). The surface coverage values of N_{1s} were similar to those of C_{1s}, as both are covalently bonded, except
16 285 for **Si-1** wafers, which had less coverage as compared to values of C_{1s} (35 % vs 57 %), suggesting that some
17 286 linkers on the monolayer do not react with 4,4'-bipyridine during stage 4 probably as a result of the tightly packed
18 287 SAM. Similarly, the surface coverage of the elements of the counter anion (Br_{3d}, I_{3d}, F_{1s}, and P_{2p}) is considerably
19 288 lower than C_{1s}, suggesting that the counter anions might be exchanged during washes.

20 289 Moreover, the fluorescence of compound **3** was further used for assessing the functionalization of **Si-3** wafers
21 290 using confocal fluorescence microscopy (See Supporting Information, Figure S 4). Homogeneous fluorescence was
22 291 observed across the surface, suggesting the successful formation of a monolayer.


23 292 *Functionalization of Si μ P in suspension*

24 293 Polysilicon microparticles (**Si μ P**) previously collected in suspension were functionalized following a similar
25 294 protocol to the one previously used for the silicon wafers (Figure 3) but adapted to the microparticles. For instance,
26 295 reactions were carried out in Eppendorf tubes with typical reaction volumes of 100 μ L. Sonication was used
27 296 periodically (including at the beginning of each reaction) to induce homogeneous suspension of the microparticles,
28 297 which was later maintained using vortex stirring. After each reaction, the microparticles were washed with
29 298 centrifugation-resuspension cycles using the same solvent to remove excess reactants, then with acetone to
30 299 remove the previous solvent, and the particles were finally dried using a stream of nitrogen. After the cleaning
31 300 and activation step (performed in water) (stage 2), IPA and DMF were used as cosolvents to promote the
32 301 sedimentation of the particles during the washes and decrease the particle loss. The functionalization strategy
33 302 including the reaction conditions can be seen in the Supporting Information (Figure S 5). First, the microparticles
34 303 with no previous treatment (**Si μ P**) (stage 1) were subjected to a cleaning and activation step by using acid and
35 304 basic treatment, providing the silicon surface with hydroxyl groups (stage 2). Activated microparticles were
36 305 immersed in a solution of silane-bearing linkers that react with the hydroxyl groups of the **Si μ P** (stage 3).
37 306 Appropriate second linkers and/or compounds containing bipyridinium moieties were then covalently conjugated
38 307 to the microparticles (stages 4 and 5).

39 308 As achieving homogeneous functionalization of microparticles in suspension remains a challenging task, the
40 309 fluorescence of compound **3** was used to study the functionalization of **Si μ P-3** microparticles using confocal
41 310 fluorescence microscopy. Figure 5 (A) shows the fluorescence of **3** being in colocalization with the microparticles,
42 311 while 3D-projections of transmission/fluorescence composites Figure 5 (B) show that the fluorescence is indeed
43 312 localized on the surface of the microparticles, proving their functionalization. Furthermore, the homogeneity of
44 313 the functionalization was studied by quantifying the fluorescence across four different sections of the
45 314 microparticles (axes a - d), as shown in Figure 5 (C), and the data were plotted in an overlapped manner (Figure
46 315 5, D). The fluorescence intensity profiles for particles 1 and 2 display a constant intensity across the particle
47 316 (according to the sensitivity of the technique), which shows they are homogeneously functionalized with **3**. In

1
2
3 317 contrast, intensity profiles for particle 3 show a decrease in the fluorescence in the central part of the plot, showing
4 318 a lack of functionalization in the center of the particle. The mean fluorescence intensity from each axis was
5 319 quantified (Figure 5, E) (n = 131 pixels measured), observing no differences between the four different axes (a -
6 320 d) for each particle; however, different mean intensities can be observed when comparing between particles
7 321 (Figure 5, F) (n = 524 pixels measured). For example, particle 2 shows around 20 % less intensity than particle 1,
8 322 whereas particle 3 shows around 48 % less intensity than particle 1 ($P < 0.0001$), evidencing a much more difficult
9 323 chemical functionalization in suspension as compared to reactions taking place in solution. One-way Analysis of
10 324 Variance (ANOVA) analysis with a Bonferroni's multiple comparison test can be seen in the Supporting
11 325 Information (Table S 5).

12
13
14 326
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



327
328
329
330
331
332
333
334
335


Figure 5. Characterization of **Si μ P-3** microparticles using confocal fluorescence microscopy. A) Z-projection images of representative **Si μ P-3** microparticles observed under brightfield microscopy (left), fluorescence at $\lambda_{ex} = 405$ nm and $\lambda_{em} = 420$ -600 nm (center), and overlapped images (right). B) 3D-projections of **Si μ P-3** microparticles shown under different angles prove the localization of the fluorescence on the surface of the microparticles. C) The fluorescence intensity of the surface of the microparticles was analyzed across four different axes (a-d) in each particle as shown. D) Fluorescence intensity profiles along the axes were obtained using ImageJ and are plotted together with the transmitted light intensity profiles. E) The mean fluorescence intensity of each axis in each particle is plotted. Values represent Means \pm SD ($n = 131$ pixels). F) The mean fluorescence intensity for each particle is plotted. Values represent Means \pm SD ($n = 524$ pixels). ***Significant differences ($P < 0.0001$).

1
2
3 336
4
5 337 *Particle count*
6 338 In order to quantify the total number of particles recovered after functionalization, unfunctionalized **S μ P** and
7 339 functionalized **S μ P-1**, **S μ P-2**, and **S μ P-3** particles were counted in transparent 96-well plates using a
8 340 Lionheart FX automated microscope (see Supporting Information, Tables S 6 and S 7). The results show that an
9 341 important number of particles are lost during functionalization depending on factors such as the number of
10 342 reactions taking place, the number of washes performed after each reaction, and the type of solvents used.
11 343 Unfunctionalized particles (**S μ P**), which are initially suspended in ethanol, are washed several times with water
12 344 for removing ethanol completely before performing experiments with cells (stage 1). In the case of functionalized
13 345 particles (**S μ P-1**, **S μ P-2** and **S μ P-3**), the activation step (stage 2) involves the use of a high proportion of
14 346 water during the acid and basic treatments (while the resulting hydroxyl groups on their surface increase their
15 347 polarity). Therefore, the highest fraction of unfunctionalized particles (≥ 90 %) are lost during washing (stage 1),
16 348 whereas most functionalized particles are lost during activation (stage 2). After activation, functionalization of
17 349 **S μ P-1** involves the use of less-polar organic solvents, permitting proper sedimentation and thus the highest
18 350 particle recovery (95.1 ± 13.9 %) with respect to washed unfunctionalized particles (**S μ P**). In contrast, the
19 351 functionalization of **S μ P-2** and **S μ P-3** leads to recoveries of 33 ± 4.1 % and 58 ± 32 %, respectively, as a more
20 352 polar solvent (ethanol) is used, while the functionalization involves 5 and 4 stages, respectively.

24 353 *Internalization of unfunctionalized microparticles (S μ P) in HeLa cells*

25 354 The internalization of unfunctionalized microparticles (**S μ P**) in cancerous HeLa cells was studied by adding
26 355 different amounts of **S μ P** to the cells. Considering the impossibility to know the exact number of cells in wells
27 356 before incubation due to great variability in biological systems, the approximate number of cells was estimated
28 357 according to the confluency. For instance, cells grown to ≈ 80 % confluency (ca. 100,000 cells per well) were
29 358 treated with the microparticles, leading to approximate **S μ P**:cells ratios of 0.04:1, 0.08:1, 0.17:1, and 0.33:1. After
30 359 24-h incubation, the cells were observed under brightfield microscopy (See Supporting Information, Figure S 6).
31 360 The results show that HeLa cells can uptake one or more **S μ P** per cell, where a higher number of particles added
32 361 results in a higher number of particles internalized per cell. The cells remained healthy according to continuation
33 362 of division even at the highest dose tested (ca. **S μ P**:cells ratio 0.33:1). To further confirm the intracellular
34 363 localization of the particles and eliminate the possibility of them being attached only to the membrane, confocal
35 364 fluorescence microscopy was used. Cells were incubated for 24 h with 20 or 40 μ L of suspended microparticles
36 365 (**S μ P**:cells ratios 0.08:1 or 0.17:1, respectively) prior to observation. Figure 6 shows that the particles are localized
37 366 in the same focal plane as actin fibers and nuclei, confirming the internalization into HeLa cells, while no damage
38 367 of the nuclear structure or the cytoskeletal framework is observed.

42 368
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



21 371
22 372
23 373
24

Figure 6. Confocal fluorescence microscopy images of HeLa cells after 24 h incubation with **SiμP** (unfunctionalized) at **SiμP:cells** ratios 0.08:1 (top) and 0.17:1 (bottom). Cells were stained with Phalloidin (targets filamentous actin) and Hoechst 33342 (targets DNA), and microparticles were observed in reflectance mode. Images were taken at 63x magnification. Scale bar is 20 μm.

25 374 Cytotoxicity of functionalized microparticles in HeLa cells

26 375
27 376
28 377
29 378
30 379
31 380
32 381
33 382
34 383
35 384
36 385
37 386
38 387
39 388
40 389
41 390
42
43
44


The cytotoxicity of functionalized (**SiμP-1**, **SiμP-2**, and **SiμP-3**) and unfunctionalized (**SiμP**) microparticles in HeLa cells was studied at using confocal fluorescence microscopy. Microparticles in suspension (20 or 40 μL) were added to the cells, whereas PBS (20 or 40 μL) was added as a control (untreated), and cells were incubated for 24 h. Afterwards, cells were treated with live/dead staining, through which viable cells can be identified by their green fluorescence, as a result of the enzymatic activity of esterases, whereas dead cells are identified by red fluorescence, as a result of the binding of ethidium homodimer-1 to DNA, indicating loss of cell- and nuclear-membrane integrity. Samples were washed several times with PBS to remove non-internalized microparticles or fluorophore, as well as detached (nonviable) cells and were imaged at $\lambda_{ex} = 488$ nm and $\lambda_{em} = 520-560$ nm (green), or $\lambda_{ex} = 600$ nm and $\lambda_{em} = 635-700$ nm (red). In parallel, samples were imaged in brightfield mode to observe the microparticles and the morphology of cell membranes, while reflectance-mode data was acquired in some samples for easier visualization of the microparticles (shown in cyan). Figure 7 (A-J) shows the overlapped 3D-projections from the different focal planes acquired of the cells incubated with 20 μL (top) or 40 μL (bottom) of PBS (A-B) or a suspension of unfunctionalized (**SiμP**) (C-D) or functionalized **SiμP-1** (E-F), **SiμP-2** (G-H), or **SiμP-3** (I-J) microparticles. Pale blue arrows point to cells with particles internalized, while red arrows point to nonviable cells, either those with loss of cell membrane integrity, identified by a bumpy cell membrane, or those with loss of nuclear membrane integrity as well, identified by red fluorescence.

45 391
46 392
47 393
48 394
49 395
50 396
51 397
52 398
53 399
54 400
55
56
57
58
59
60

The *cell viability* [%] respect to the untreated sample was estimated according to the esterase activity of cells by quantifying the fluorescence intensity in the green channel. The *cell viability* was calculated following two complementary approaches. In the first approach, the fluorescence in the entire images was quantified, and values reflect the total esterase activity in the sample (Eq. 1). Thus, the total esterase activity is influenced by the number and size of cells (confluency) remaining as well as by the esterase activity of each cell, in a similar way as in other conventional methods in solution such as MTT.⁵⁹ In the second approach, the mean fluorescence in the cells is quantified, for which values are not influenced by the number and size of cells remaining, but they specifically reflect the esterase activity within cells (Eq. 2) (See Supporting Information, Figure S 7). Hence, the comparison of *cell viability* values using both approaches could provide information about the number and size of cells after treatment. The *cell viability* values observed after incubation with the microparticles were plotted as a function of

401 the **Si μ P**:cells ratio of the sample (Figure 7, K), showing a dose-response relationship. In fact, values obtained
 402 using the total esterase activity (top) or the mean intracellular activity (bottom) were generally similar, showing
 403 a correlation between the intracellular esterase activity and cell confluency.

404



405
 406 *Figure 7. A-J) Confocal fluorescence microscopy images of untreated [A-B] HeLa cells or after 24-h incubation with either 20 μ L (top) or 40*
 407 *μ L (bottom) unfunctionalized (Si μ P [C-D]) or functionalized (Si μ P-1 [E-F], Si μ P-2 [G-H], or Si μ P-3 [I-J]) microparticles. Cells were*
 408 *washed with PBS after incubation to remove non-internalized microparticles as well as detached cells. Live/dead staining was applied to*
 409 *observe cells showing activity of intracellular esterases (green) and cells with cell and nuclear membrane integrity loss leading to DNA*
 410 *exposure (red). Sample was observed at $\lambda_{ex} = 488$ nm and $\lambda_{em} = 520$ -560 nm (green), or $\lambda_{ex} = 600$ nm and $\lambda_{em} = 635$ -700 nm (red).*
 411 *In parallel, samples were observed in brightfield mode to detect cell membranes and microparticles, while reflectance mode was acquired in*
 412 *some samples for easier visualization of the microparticles (shown in cyan). Images are displayed as projections of the different focal planes*
 413 *acquired. Pale blue arrows indicate the cells with particles internalized. Red arrows indicate nonviable or lysed cells as identified by their*
 414 *bumpy cell membrane morphology or DNA exposure. Scale bar is 30 μ m. K) Viability of HeLa cells upon 24 h incubation with different*

1
2
3 415 **S μ P**:cell ratios of unfunctionalized (**S μ P**) and functionalized (**S μ P-1**, **S μ P-2**, or **S μ P-3**) microparticles. Cell viability is expressed as
4 416 a percentage of total esterase activity in the sample ($n=3$) with respect to untreated cells (top) or mean intracellular esterase activity ($n\geq 10$)
5 417 with respect to untreated cells (bottom) as measured by fluorescence intensity in the green channel. Values represent Means \pm SD. L.
6 418 Cytotoxicity per particle [cell/**S μ P**] was obtained both according to the total esterase activity (top) or the mean intracellular esterase
7 419 activity (bottom). M) Cytotoxicity per bipy [cell/bipy] was obtained according to the cytotoxicity per particle and total number of
8 420 bipyridinium moieties conjugated per particle. Values represent Means \pm SD. Statistical significance: groups with sharing Greek letters show
9 421 no significant differences ($P>0.05$), whereas groups with different letters are significantly different ($P<0.05$).

10
11 422
12 423 Untreated Hela cells (Figure 7, A-B) are mostly healthy after incubation and show the highest esterase activity,
13 424 while few dead cells are observed. In treated cells (Figure 7, C-J), most particles are internalized (pale blue arrows),
14 425 but also some of them are observed outside the cells, and even some are embedded in the cell membrane, (e.g.
15 426 Figure 7, D, center). Washing the cells several times before being imaged suggests that those particles outside the
16 427 cells were most probably previously internalized, and were later released from the cells due to their loss of
17 428 membrane integrity, for which it is possible that particles can be internalized in more than one cell during
18 429 incubation.

20
21 430 The cells treated with unfunctionalized (**S μ P**) microparticles showed 76 % intracellular esterase activity and 80
22 431 % total esterase activity at a 0.08:1 **S μ P**:cells ratio, showing very mild toxicity in accordance to previous results.³⁷⁻
23 432 ⁴⁰ In contrast, functionalized microparticles induce a higher toxicity in a dose-response relationship. Incubation
24 433 with **S μ P-1** (E-F) results in a high proportion of cells with blebbing on the cell membrane, indicating start of
25 434 apoptosis, and decreased green fluorescence, leading to 13.3 % mean intracellular esterase activity and 0.4 % total
26 435 esterase activity at $\approx 0.16:1$ **S μ P**:cells ratio. **S μ P-2** (G-H) shows the highest cytotoxic effect on Hela cells, where
27 436 the particles are colocalized with cells but only unviable cells are observed even at the lowest **S μ P**:cells ratio
28 437 ($\approx 0.03:1$) (G), and lead to only 5.9 % esterase activity, either intracellular or total. **S μ P-3** particles (I-J) show in
29 438 some cases more than one particle internalized per cell, and although very few nonviable cells can be seen, 60.7
30 439 % intracellular esterase activity is observed at $\approx 0.03:1$ **S μ P**:cells ratio, while 59.2 % at the highest ($\approx 0.06:1$)
31 440 **S μ P**:cells ratio tested. Interestingly, incubation with **S μ P-3** within this range of **S μ P**:cells ratios did not show
32 441 a dose-response decrease of the mean intracellular esterase activity, but did of the total esterase activity,
33 442 evidencing a decrease in cell confluency.

34
35
36 443 Comparisons between the different particles were made by calculating the *cytotoxicity per particle* [cell/**S μ P**]
37 444 (Eq. 3), an extrapolated value that considers the *cell viability* and the number of particles dosed (Figure 7, L). As
38 445 the *cell viability* reflects the overall enzymatic activity of cells, the *cytotoxicity per particle* describes the overall
39 446 damage to cell activity, and represents the equivalent number of cells that can die per particle administered if the
40 447 remaining live cells maintained their esterase activity. For instance, unfunctionalized particles (**S μ P**) showed very
41 448 low *cytotoxicity per particle* (1.9 ± 0.5 cell/**S μ P** according to the total esterase activity). In contrast, all
42 449 functionalized particles showed significantly higher toxicity. The highest *cytotoxicity per particle* was achieved by
43 450 **S μ P-2**, (25.5 ± 8.4 cell/**S μ P**), higher than the rest ($P<0.001$). On the other hand, **S μ P-3** shows a *cytotoxicity*
44 451 *per particle* similar or slightly lower than **S μ P-1** (4.9 ± 0.8 cell/**S μ P** vs 6.4 ± 0.1 , respectively). However, according
45 452 to XPS measurements, **S μ P-1** particles show the highest surface coverage (ca. 14 moieties per nm²), whereas
46 453 **S μ P-3** show the lowest (ca. 2 moieties per nm²). Taking in account these differences, the *cytotoxicity per bipy*
47 454 [cell/bipy], was also calculated according to the total number of bipyridinium units conjugated per particle (Figure
48 455 7, M). In this line, there is a 2.7-fold higher *cytotoxicity per bipy* of **S μ P-3** as compared to **S μ P-1** evidencing
49 456 the importance of both the number of bipyridinium units in the cells and their arrangement on the surface of the
50 457 microparticles. The cyclic structure of **3** leads to a less densely packed layer of bipy units conjugated in **S μ P-3**,
51 458 which could favor its interaction with dissolved oxygen to generate ROS, achieving more efficiency in ROS
52 459 generation as compared to **S μ P-1**. On the other hand, **S μ P-2** show 2.6-fold higher *cytotoxicity per bipy* than
53 460 **S μ P-3**. As both compounds **2** and **3** have a cyclic structure, the lower *cytotoxicity per bipy* of **S μ P-3** may be

1
2
3 461 influenced by the *p*-phenylene spacer in the bipyridinium units. According to DPV experiments, the redox
4 462 transition of **3** occurs at a slightly lower potential than **1** or **2**, which may possibly account for a lower ROS
5 463 generation and therefore lower cytotoxicity.

7 464 In solution, compounds bearing one bipyridinium moiety show IC_{50} values in cancerous cells ranging from 5.6 to
8 465 240 μM ,⁵² some of them showing even higher cytotoxicity than cisplatin (IC_{50} 15 to 142 μM). Thus, the equivalent
9 466 concentration of compounds **1**, **2**, and **3** conjugated on the particles was estimated as if they were in solution (see
10 467 Supporting Information, Table S 8). For instance, **Si μ P-1** show 48.4 % cell viability when they are dosed at 22.1
11 468 nM of compound **1**, whereas **Si μ P-3** show 49.6 % viability at 3.6 nM of **3**, and **Si μ P-2** only show 5.9 % cell
12 469 viability at 2.2 nM of **2**, evidencing an increased cytotoxicity when bipyridinium moieties are conjugated onto the
13 470 microparticles.

15 471 The mechanism of toxicity of compound **1** in solution, which has been widely studied *in vitro*, using cell cultures,
16 472 and *in vivo*,^{50,51,60,61} involves the initial generation of superoxide anion, the formation of oxygen radicals, and the
17 473 further lipid peroxidation, a radical chain reaction that spreads across polyunsaturated fatty acids (PUFA) of the
18 474 cell membranes. The cytotoxicity mechanism is schematized and explained in the Supporting Information (Figure
19 475 S 8). Although ROS are formed and lipid peroxidation occurs in healthy cells at basal levels, the extent of the
20 476 oxidative state of cells determines their fate, where low levels of ROS and lipid peroxidation trigger the endogenous
21 477 antioxidant systems (glutathione, vitamin E, superoxide dismutase, catalase, glutathione peroxidase) to counteract
22 478 oxidation; but in contrast, high levels of lipid peroxidation trigger apoptosis or programmed necrosis.⁶⁰

25 479 To observe if bipyridinium-functionalized microparticles follow a similar pathway, confocal fluorescence
26 480 microscopy was used to image Hela cells upon being treated for different times with compound **1** in solution (100
27 481 μM , within the reported IC_{50} values) or with **Si μ P-1** at lower doses (**Si μ P**:cells 0.002:1 to 0.008:1). Cells were
28 482 treated with CellROX® orange as a generalized fluorescent sensor to detect ROS in the cytoplasm, and were
29 483 observed at λ_{ex} 561 nm and λ_{em} 566-759 nm (orange-red). In parallel, brightfield mode and blue emission (λ_{ex} 405
30 484 nm and λ_{em} 410-471 nm) were acquired to observe changes in cell morphology and composition. It has been
31 485 reported that the spontaneous photon emission (SPE), occurring in lipid peroxidation, is attributed to excited
32 486 states created during oxidative metabolic reactions. The main source of SPE is the slow spontaneous
33 487 decomposition of lipid peroxides and endoperoxides, generating species such as singlet oxygen and excited triplet
34 488 carbonyl groups. As well, the bimolecular reaction of alkoxy radicals lead to excited triplet carbonyl groups. Upon
35 489 relaxation, excited carbonyl groups emit light in the blue region, whereas the bimolecular reaction of singlet
36 490 oxygen emits light in the red region. Thus, imaging their luminescence could be used as a non-destructive
37 491 technique capable of detecting lipid peroxidation in tissues.^{61,62}

40 492 Figure 8 shows overlapped Z-projections of untreated cells, or cells treated with compound **1** for 1, 2, 4, or 24 h,
41 493 or treated with **Si μ P-1** for 2, 4, or 24 h. After either 1 or 2-h incubation with **1** in solution, the cells start to show
42 494 signs of lipid peroxidation, being less transparent in the brightfield than untreated cells, which indicates either
43 495 change in the composition or in the arrangement of the lipid bilayer, and showing higher number of vesicles of
44 496 400 - 900 nm in diameter. Higher blue emission was observed in these cells, especially coming from the vesicles,
45 497 suggesting accumulation and reaction of alkoxy and peroxy lipid radicals during lipid peroxidation. Incubation
46 498 for longer times (4 or 24 h) shows increased signs of lipid peroxidation, including the blebbing of the cell
47 499 membrane, indicating start of apoptosis, also observed in Figure 7.

50 500 In contrast, a higher extent of lipid peroxidation is associated to lower cytosolic ROS levels. After 2-h incubation
51 501 cytosolic ROS concentrations remained similar to those of untreated cells (see Supporting Information Figure S
52 502 9), but decreased significantly after 4-h incubation. The ROS species induced by bipyridinium (initial superoxide
53 503 and subsequent hydroxyl and peroxy radicals) show very low stability. Whereas the estimated half-life of H_2O_2 is
54 504 10^{-3} s, and permits its diffusion to 1 μm from its origin,⁶³ the half-life of hydroxyl radical ($\cdot\text{OH}$) is around 10^{-6} s,⁶⁴

1
2
3 505 and that of superoxide ($O_2^{\bullet-}$) is only 10^{-9} s, indicating that they should immediately react with directly proximal
4 506 substrates such as proteins and PUFA in the cell membrane.⁶³ The lipid radicals formed can in turn react with
5 507 molecular oxygen and other ROS in the cytoplasm, leading to their eventual depletion.
6
7 508
8
9 509
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 8. Confocal fluorescence microscopy images (Z-projections) of (A) untreated HeLa cells, or HeLa cells treated with (B) 100 μM **1** in solution for 1, 2, 4, or 24 h, or treated with **Si μ P-1** at (C) **Si μ P:cells** 0.002:1, (D) **Si μ P:cells** 0.004:1, (E) **Si μ P:cells** 0.008:1, for 2, 4, or 24 h. Upon 4-h incubation with **1**, important lipid peroxidation occurs leading to changes in cell morphology, with decreased transparency (brightfield), increased blue-emission, and decreased cytosolic ROS (red). Incubation with **Si μ P-1** for 2 h leads to important lipid peroxidation, similar to that observed with 4-h incubation with **1** in solution. Scale bar represents 40 μm .

1
2
3 516 Incubation with **SiμP-1** for 2 h, already at the lowest dose (**SiμP**:cells 0.002:1), led to significantly lower cytosolic
4 517 ROS and important lipid peroxidation, similar to the 4-h incubation with **1** in solution. Lipid peroxidation starts
5 518 in the cells internalizing particles, and spreads out across the proximal cells, as observed in **¡Error! No se**
6 519 **encuentra el origen de la referencia.** D, 4 h. At the lowest dose, the equivalent concentration of bipyridinium
7 520 units is 0.6 nM if they were in solution, evidencing a much higher efficiency when they are onto the microparticles.
8 521 The close contact of the particles with the cell membrane due to strong multivalent interactions between the
9 522 microparticles and the cell membrane, and due to sedimentation, might facilitate superoxide, hydroxyl, and
10 523 peroxy radicals to react with PUFA molecules, greatly increasing the speed of lipid peroxidation as compared to
11 524 solution.

12
13
14 525 The membrane integrity loss induced by the microparticles was also confirmed by incubating Hela cells with the
15 526 microparticles at low confluency ($\approx 10\%$) and higher **SiμP**:cells ratios, permitting an easier observation of their
16 527 morphology and their interaction with the particles (see Supporting Information, Figure S 10). After 24-h
17 528 incubation, the cells internalizing particles can completely lose their membrane integrity and release the
18 529 microparticles, evidencing that each particle could be internalized in more than one cell during incubation. As
19 530 observed by their morphology, apoptosis occurs not only in cells with particles internalized, but also on the
20 531 neighboring cells, similar to observations at lower confluency (Figure 7 and Figure 8), in line with the radical
21 532 chain reaction spreading across membranes.

22
23
24 533 These observations suggest that the mechanism of cytotoxicity of the bipyridinium-functionalized microparticles
25 534 is similar to that of compound **1** in solution, but the microparticles can induce the cytotoxic effects in shorter times
26 535 and to a much higher extent, with strong dependence on the number and type of particles administered.

27
28 536 Nonetheless, their high stability and self-renewing ability could possibly lead to further toxicity effects if they are
29 537 left within the body. Even though it is true that polysilicon could be oxidized intracellularly to silicon oxide over
30 538 time, and the latter can be biodegraded by dissolution of silicic acid into the aqueous medium,⁶⁵ the removal of
31 539 the particles after exerting their toxicity could be considered. As their negligible self-diffusion helps the particles
32 540 remain in place, they could be removed depending on the characteristics of the tumor tissue (surgical removal /
33 541 suction techniques as in liposuction procedures). The administration of antioxidants such as α -tocopherol
34 542 (vitamin E) could help stopping the radical chain reactions remaining in surrounding tissues, as they can react
35 543 with lipid radicals becoming stable radicals.³⁵ Nonetheless, its high lipophilicity limits its distribution and diffusion
36 544 across tissues, for which the administration of water-soluble analogs, or the use of liposomal preparations are
37 545 needed to improve their efficacy.⁵¹

38
39
40 546

41 42 547 **Conclusions**

43 548 As a suitable system to improve the efficacy and selectivity towards cancerous cells, bipyridinium-derived
44 549 compounds **1**, **2**, and **3** were selected for their ability to induce cytotoxicity in a range of potentials normally
45 550 achieved in intracellular conditions and in a self-renewing fashion, and were covalently conjugated onto
46 551 polysilicon microparticles (**SiμP**). The system was designed to increase the selectivity by means of three aspects:
47 552 the size of microparticles eliminating their diffusion to surrounding tissues, the EPR effect maximizing their
48 553 retention within the tumor, and the covalent immobilization of compounds onto the microparticles avoiding their
49 554 release to solution and further diffusion.

50
51 555 Microparticles can be homogeneously functionalized with bipyridinium-containing compounds of different
52 556 architectures, where the open chain structure of **1** permits a more densely packed SAM than the cyclic structures
53 557 of **2** and **3**. They can be well internalized in cancerous Hela cells leading to several cytotoxic effects, including ROS-
54 558 mediated lipid peroxidation, nuclear and cell membranes integrity loss, and overall decreased viability as observed

1
2
3 559 by intracellular and total esterase activity. Unfunctionalized particles are mainly non-cytotoxic, whereas
4 560 bipyridinium-functionalized induce lipid peroxidation in their host cell and in the neighboring cells in less than 2
5 561 h. Functionalized particles importantly reduce cell viability at very low **SiμP**:cells ratios, leading to
6 562 *cytotoxicity per particle* values of 6.4 ± 0.7 , 25.5 ± 8.4 , and 4.9 ± 0.8 cell/**SiμP**, for **SiμP-1**, **SiμP-2**, and **SiμP-3**,
7 563 respectively. Considering the number of moieties conjugated, the *cytotoxicity per bipy* values suggest that the less
8 564 densely packed arrangement of bipyridinium units in cyclic structures (**SiμP-2** and **SiμP-3**) may account for a
9 565 higher cytotoxic efficiency than in an open chain structure (**SiμP-1**). Nonetheless, the extended structure of
10 566 bipyridinium (**SiμP-3**) may decrease their efficiency as compared to non-extended (**SiμP-2**), in line with the
11 567 lower reduction potential in solution. The compounds conjugated display cytotoxicity at doses representing
12 568 nanomolar concentrations if they were in solution, 3 orders of magnitude below IC_{50} values reported.

15 569 The highly efficient cytotoxicity of bipyridinium-functionalized microparticles might be promoted by their self-
16 570 renewing ability, their possibility to internalize in more than one cell, and their proximity to the cell membrane
17 571 due to strong multivalency interactions and sedimentation, facilitating the immediate reaction of the oxygen
18 572 radicals with PUFA and increasing the speed of lipid peroxidation. The great extent of lipid peroxidation in short
19 573 incubation times, and at low concentration of microparticles or bipyridinium units, is in line with the decreased
20 574 cell viability induced, where the overall cytotoxic efficiency is reflected in the high *cytotoxicity per particle* and
21 575 *cytotoxicity per bipy* values observed.

24 576 The fabrication of the **SiμP** based on silicon technologies allows a high reproducibility and control of the
25 577 microparticles dimensions. The microparticles can be observed even under simple brightfield and fluorescence
26 578 microscopies. They could be directly injected in suspension within the tumor, with control over the number of
27 579 particles and the amount of compound administered, and could be further eliminated upon removal of the
28 580 damaged tissue and treatment with antioxidants such as vitamin E. Looking to the future, the inclusion of
29 581 magnetic materials during particle fabrication could improve their controlled elimination, while their possibility
30 582 for hybrid functionalization could combine more functionalities in a single silicon chip, for example, the
31 583 conjugation of antibodies on their surface may also provide increased active tumor targeting.^{14,66}

34 584 **Materials and Methods**

36 585 *Materials and solvents*

37 586 MilliQ water (18 MΩ cm) was used in all the experiments. Dichloromethane 99.8 % (DCM), *N,N*-Dimethyl
38 587 formamide (DMF), Isopropanol (IPA), Ethanol (EtOH), Sulfuric acid 98 % (H₂SO₄), Hydrogen peroxide solution
39 588 30 % (H₂O₂), Ammonium hydroxide solution 28 % (NH₄OH), Ethanol, Acetone (99.5 %), Acetonitrile anhydrous
40 589 (99.8 %) (MeCN), (3-Aminopropyl)triethoxysilane (APTES), and 11-Bromoundecyltrichlorosilane 95 % (BUTCS)
41 590 were purchased from abcr, Iodomethane 99 %, Propargyl chloride, Triethylamine (Et₃N), *N*-Hydroxysuccinimide
42 591 (NHS), *N*-(3-Dimethylaminopropyl)-*N'*-ethylcarbodiimide hydrochloride (EDC), Tetrabutylammonium
43 592 hexafluorophosphate (TBA·PF₆), Copper(I) bromide (CuBr), *N,N,N',N',N''*-Pentamethyldiethylenetriamine
44 593 (PMDETA), (+)-Sodium L-ascorbate, tributylamine, 4,4'-Bipyridine, Parafilm® M, Phosphate-buffered saline
45 594 (PBS) tablets, and Live/Dead Cell Double Staining Kit were purchased from Sigma. Hoechst 33342,
46 595 Trihydrochloride, Trihydrate - 10 mg/mL Solution in Water and Gibco Dulbecco's Modified Eagle Medium
47 596 (DMEM) were purchased from Thermo Fisher Scientific. Image-iT Fixative Solution (4 % formaldehyde,
48 597 methanol-free) (PFA) was purchased from Invitrogen. ROS fluorescent probe 2',7'-Dichlorofluorescein diacetate
49 598 was purchased from Cayman chemical.

53 599 *Solutions*

1
2
3 600 Piranha solution was prepared by mixing H₂SO₄ with H₂O₂ solution in a proportion of 7:3 (v:v). Basic solution was
4 601 prepared by mixing NH₄OH solution with H₂O₂ solution and water in a proportion of 1:1:5 (v:v:v). PBS (10 mM
5 602 phosphate) solution was prepared according to manufacturer's instructions.

603 *Synthesis of bipyridinium compounds*

604 Compound **1** was synthesized by dissolving 4,4'-bipyridine (0.5 g, 3.2 mmol) in dry MeCN (100 mL) under
605 magnetic stirring. Methyl iodide (4.54 g, 32 mmol) was added and the solution was kept under reflux for 24 h.
606 The orange-red solid precipitate was filtered under vacuum, washed thoroughly using MeCN and acetone. The
607 precipitate was dissolved in water and a saturated aqueous solution of ammonium hexafluorophosphate was
608 added. The precipitate was recovered by centrifugation, after which the supernatant was removed, and the solid
609 was further washed by resuspension-centrifugation cycles using water (3 x 1 mL). The solid was dried overnight
610 under vacuum to obtain compound **1**. Purity was confirmed by TLC and identity was confirmed by ¹H NMR.
611 Compound **2** was synthesized by adapting a protocol for the synthesis of the azide-substituted *bluebox* (CBPQT⁴⁺-
612 N₃),⁶⁷ and compound **3** was synthesized by adapting a protocol for the synthesis of the *m*-ExBox.⁶⁸ The synthesis
613 and molecular characterization of **2** and **3** will be published elsewhere.

614 *Differential Pulse Voltammetry (DPV)*

615 DMF was degassed in a sealed vial with a stream of nitrogen for 10 min and was used in all the DPV experiments.
616 The working vial and the reference electrode were cleaned with DMF. 1 mg of compound (either **1**, **2**, or **3**) was
617 dissolved in degassed DMF (1 mL) containing TBA·PF₆ and was placed in the working vial. Additional degassed
618 DMF (2 mL) was added to reach enough volume to cover the electrodes. A working electrode, a Pt counter
619 electrode, and a reference electrode (ground) were mounted in the working vial and the system was sealed with
620 parafilm®. Nitrogen was bubbled through the solution for an additional 3 min. DPV analyses of the three different
621 compounds in solution were acquired using Gamry Framework software, setting the analysis from 0.5 V to -2.5
622 V with a scan rate of 100 s⁻¹ and a step size of 5 mV.

623 *Cleaning and activation of silicon wafers*

624 **Stage 1:** Wafers (0.25 cm²) were first washed with water (2 x 5 mL) and ethanol (2 x 5 mL) and then dried with a
625 stream of nitrogen. **Stage 2:** Subsequently, the wafers were activated by immersing them in piranha solution for
626 one hour at room temperature under orbital shaking, after which the wafers were rinsed with water (2 x 5 mL)
627 and dried with a stream of nitrogen. Wafers were then immersed in basic solution for 30 min at room temperature
628 under orbital shaking, rinsed with water (2 x 5 mL), and dried with nitrogen.

629 *Functionalization of silicon wafers with 1 (Si-1)*

630 **Stage 3:** Previously activated wafers (Stages 1 and 2) were immersed in a 5 % solution of BUTCS solution in DCM
631 and were left under orbital shaking overnight at room temperature, after which they were rinsed with DCM (2 x 5
632 mL) and dried with a stream of nitrogen. **Stage 4:** Wafers were immersed in a 43 mM solution of 4,4'-bipyridine
633 in IPA and were left under orbital shaking overnight at room temperature, after which they were rinsed with IPA
634 (2 x 5 mL) and dried with nitrogen. **Stage 5:** Finally, wafers were immersed in a 200 mM solution of iodomethane
635 in DCM and were left under orbital shaking for 48 h at room temperature. Wafers were rinsed with DCM (2 x 5
636 mL) and dried with nitrogen.

637 *Functionalization of silicon wafers with 2 (Si-2)*

638 **Stage 3:** Previously activated wafers (Stages 1 and 2) were immersed in a solution of APTES in ethanol (1:19) and
639 were left at room temperature under orbital shaking for 3 h, after which wafers were washed with ethanol (2 x 5
640 mL) and acetone (2 x 5 mL) and dried with a stream of nitrogen. **Stage 4:** Wafers were immersed in a solution
641 containing 120 mM propargyl chloride, 60 mM tributylamine, and 60 mM triethylamine in DCM and kept at room

1
2
3 642 temperature under orbital shaking for 7 h. Afterwards, wafers were rinsed with acetone (2 x 5 mL) and dried with
4 643 a stream of nitrogen. **Stage 5:** Wafers were immersed in a solution containing 10 mM **2**, 0.1 mM CuBr, 0.1 mM
5 644 PMDETA, and 5 mM sodium ascorbate in DMF:H₂O (98:2), and the flask containing the wafers was sealed, bubbled
6 645 with nitrogen for 5 min, and kept overnight at room temperature with magnetic stirring. Afterwards, wafers were
7 646 washed with DMF (2 x 5 mL) and acetone (2 x 5 mL) and dried with nitrogen.

9 10 647 *Functionalization of silicon wafers with 3 (Si-3)*

11 648 **Stage 5:** Wafers previously activated (Stages 1 and 2) and functionalized with APTES (Stage 3) were immersed in
12 649 a solution containing 0.22 mM **3**, 4.9 mM NHS, 4 mM EDC, and 0.02 % of Et₃N in MeCN and then kept under
13 650 magnetic stirring for 4 h at room temperature. Wafers were then washed with MeCN (2 x 5 mL) and acetone (2 x
14 651 5 mL) and dried with nitrogen.

16 17 652 *Contact angle measurements*

18 653 Contact angle measurements were performed in air using a Thetalite100 goniometer equipped with the software
19 654 OneAttension (Finland). A 3 μ L drop of milliQ water was applied on the surface and the mean of 10 contact angle
20 655 measurements was obtained. At least three replicates for each sample were analyzed.

22 23 656 *X-Ray Photoelectron Spectroscopy (XPS)*

24 657 Silicon oxide wafers with the polysilicon microparticles on top were analyzed using a Thermo ESCALab 250 Xi X-
25 658 Ray Photoelectron Spectroscopy (XPS) instrument controlled by ThermoFisher Avantage v5 software. A survey
26 659 was performed from each surface after each functionalization stage, and further analysis of the atomic content of
27 660 Br3d, Si2p, C1s, N1s, O1s, and I3d was performed. The atomic content of each element relative to Si2p was
28 661 obtained.

30 31 662 *Confocal fluorescence microscopy of Si-3 wafers*

32 663 **Si-3** wafers were observed in a Leica SP8 Confocal Fluorescence Microscope in the Biological Imaging Facility
33 664 (RRID:SCR_017767) at Northwestern University, controlled by FluorEscence V.35 software. A laser set at $\lambda_{\text{exc}} =$
34 665 405 nm (10 % intensity) and a HyD2 detector set at $\lambda_{\text{em}} = 420 \pm 11$ nm and smart gain 390 % were used to
35 666 observe fluorescence from **3**. The detection of the silicon surface was achieved in reflectance mode. Pinhole was
36 667 set at 1 and 8.5X zoom was used.

38 39 668 *Functionalization of Silicon microparticles (Si μ P) with bipyridinium compounds*

40 669 **Cleaning of unfunctionalized microparticles (Si μ P).** **Stage 1:** As a control for different experiments,
41 670 unfunctionalized microparticles (**Si μ P**) (ca. 1.5 million per Eppendorf) initially suspended in ethanol (1 mL) were
42 671 sedimented with centrifugation and supernatant was removed. Particles were washed with water (2 x 100 μ L)
43 672 using centrifugation-resuspension cycles (10 min, 13400 rpm) and finally resuspended in 150 μ L PBS.

44 673 **Activation of microparticles. Stage 2: Si μ P** (ca. 1.5 million per Eppendorf) initially suspended in ethanol (1 mL)
45 674 were sedimented with centrifugation and supernatant was removed. Particles were then activated by acid and
46 675 basic treatment without prior cleaning in order to decrease particle loss. Briefly, piranha solution (100 μ L) was
47 676 added, microparticles were resuspended using sonication (10 s) and left under vortex at room temperature for 1
48 677 h. Microparticles were washed with isopropanol (2 x 900 μ L) by centrifugation-resuspension cycles (10 min,
49 678 13400 rpm) and the supernatant was completely removed. Basic solution (100 μ L) was then added to each
50 679 Eppendorf tube, microparticles were resuspended using sonication and left under vortex at room temperature for
51 680 30 min. DMF (900 μ L) was added, particles were sonicated and then centrifuged (10 min, 13400 rpm), and
52 681 supernatant was removed.

1
2
3 682 **Functionalization of Si μ P–1. Stage 3:** A 1.71 mM solution of BUTCS in DCM (300 μ L) was added to previously
4 683 activated microparticles (stage 2). The suspension was sonicated for 5 min and was left under vortex stirring
5 684 overnight at room temperature. Afterwards, particles were washed with centrifugation-resuspension cycles (10
6 685 min, 13400 rpm) using DCM (1 x 800 μ L) and IPA (1 x 800 μ L), and supernatant was finally removed. **Stage 4:** A
7 686 83 mM solution of 4,4'-bipyridine in IPA (500 μ L) was added to the microparticles. The reaction was carried out
8 687 at room temperature for 3 h under sonication, after which IPA (500 μ L) was added and particles were sedimented
9 688 using centrifugation and supernatant was removed. **Stage 5:** A 800 mM solution of iodomethane in IPA (500 μ L)
10 689 was added to each tube. Microparticles were resuspended with sonication (1 min) and left under vortex for 48 h
11 690 at room temperature. Particles were washed with centrifugation-resuspension cycles using IPA (2 x 1000 μ L), and
12 691 were resuspended in acetone (1000 μ L) and stored at room temperature. Before further experiments, particles
13 692 were centrifuged, the supernatant was removed, and the remaining solvent was completely evaporated using a
14 693 stream of nitrogen (\approx 5 min) before being resuspended in the desired medium.

17 694 **Functionalization of Si μ P–2. Stage 3:** A solution (200 μ L) of APTES in ethanol (1:19) was added to previously
18 695 activated Si μ P (stage 2). The suspension was sonicated for 3 h at room temperature, after which particles were
19 696 centrifuged and the supernatant was removed. **Stage 4:** A solution containing 558 mM propargyl chloride and
20 697 788 mM Et₃N in ethanol (260 μ L) was added to the particles, and they were resuspended using sonication (30 s).
21 698 The reaction was carried out under vortex stirring overnight at room temperature, after which particles were
22 699 washed with centrifugation-resuspension cycles with ethanol (2 x 200 μ L) using sonication, and the supernatant
23 700 was finally removed. **Stage 5:** A solution containing 0.87 mM **2**, 0.087 mM CuSO₄, and 0.87 mM sodium ascorbate
24 701 in DMF:H₂O (98:2) (200 μ L) was added to the particles and they were resuspended using sonication (30 s). The
25 702 reaction was left overnight under vortex stirring at room temperature. Particles were then washed with
26 703 centrifugation-resuspension cycles using DMF:H₂O (98:2) (1 x 200 μ L) and then acetone (1 x 200 μ L). Particles
27 704 were finally resuspended in acetone (1000 μ L) and stored at room temperature. Before further experiments,
28 705 particles were centrifuged, the supernatant was removed, and the remaining solvent was completely evaporated
29 706 using a stream of nitrogen (\approx 5 min) before being resuspended in the desired medium.

33 707 **Functionalization of Si μ P–3. Stage 5:** To the microparticles previously functionalized with APTES (stage 3), a
34 708 solution containing 0.12 mM **3**, 2.65 mM NHS, and 2.08 mM EDC in DMF:H₂O:MeCN (56:31:13) (200 μ L) was
35 709 added. The particles were resuspended using sonication (30 s), and the reaction was kept overnight under vortex
36 710 stirring at room temperature. Afterwards, particles were sonicated and were washed with centrifugation-
37 711 resuspension cycles using DMF:H₂O:MeCN (56:31:13) (1 x 200 μ L) and acetone (1 x 200 μ L). Particles were finally
38 712 resuspended in acetone (1000 μ L) and stored at room temperature. Prior to conducting further experiments,
39 713 particles were centrifuged, the supernatant was removed, and the remaining solvent was completely evaporated
40 714 using a stream of nitrogen (\approx 5 min) before being resuspended in the desired medium.

43 715 *Particle count*

44 716 100 μ L PBS (1x) were added to each well in transparent 96-well plates. Previously washed unfunctionalized (Si μ P)
45 717 and functionalized (Si μ P–1, Si μ P–2, Si μ P–3) microparticles were resuspended in PBS (150 μ L) using
46 718 sonication, and 20 μ L or 40 μ L aliquots of each suspension were added to the different wells. Particles were
47 719 counted using a Lionheart FX automated microscope. ImageJ particle-count plugin was used for counting the
48 720 particles in the images. As the total sample volume in each well is known, as well as the dimensions of the region
49 721 imaged, the volume of sample observed can be calculated (see Supporting Information, Table S5). Therefore, the
50 722 total number of particles recovered after functionalization was estimated (see Supporting Information, Table S6).

53 723 *Internalization of unfunctionalized microparticles (Si μ P) in HeLa cells*

54 724 The internalization of unfunctionalized Si μ P in cancerous HeLa cells was studied using brightfield and confocal
55 725 fluorescence microscopies. Cells grown to 80 % confluency (ca. 100,000 cells per well) were treated with different

726 volumes (10, 20, 40, and 80 μL) of a suspension of microparticles (≈ 417 **Si μP** / μL) in PBS. PBS was added to a
 727 final volume of 80 μL and DMEM (100 μL) was finally added. Cells were incubated for 24 h at 37°C and 5 % CO_2
 728 and were later washed multiple times with PBS to remove non-internalized particles and detached cells. Samples
 729 were observed under brightfield microscopy using a Lionheart FX automated microscope. Images were taken on
 730 a LionheartFX (BioTek) microscope with an Olympus 10X PL FL Phase objective, yielding an image with pixel size
 731 $dx = dy = 0.658$ μm .

732 Internalization of the **Si μP** in cells was assessed by confocal fluorescence microscopy. Cells were treated with 20
 733 or 40 μL of a suspension of microparticles (≈ 417 **Si μP** / μL) in PBS (**Si μP** :cells ratios 0.08:1 or 0.17:1, respectively),
 734 and DMEM to complete a final volume of 200 μL . After 24-h incubation with the microparticles, cells were fixed
 735 with 4 % PFA and stained with Alexa Fluor® 488 Phalloidin (targets filamentous actin) and Hoechst 33342 (targets
 736 DNA). Images were taken at 63x magnification (Leica HCX PL APO 63x/1.4NA) on a Leica SP8 confocal microscope,
 737 yielding an image with pixel size of $dx = dy = 0.072$ μm . DNA was detected at $\lambda_{\text{ex}} = 405$ nm and $\lambda_{\text{em}} = 480$ -500
 738 nm. Actin was detected at $\lambda_{\text{ex}} = 488$ nm and $\lambda_{\text{em}} = 520$ -600 nm. **Si μP** were detected in reflectance mode at $\lambda =$
 739 650 nm.

740 *Cytotoxicity of functionalized microparticles in HeLa cells*

741 HeLa cells were grown to ≈ 80 % confluency (approx. 100,000 cells per well). Unfunctionalized (**Si μP**) and
 742 functionalized (**Si μP -1, Si μP -2, Si μP -3**) particles were resuspended in 150 μL PBS (1x) using sonication. Cells
 743 were treated with 20 or 40 μL of the suspensions of microparticles in PBS. Untreated cells (20 or 40 μL in PBS)
 744 were processed in parallel as a control. DMEM was then added to obtain a final volume of 200 μL . Cells were
 745 incubated (37 °C, 5 % CO_2) for 24 h, were fixed with 4 % PFA, and stained with Live/Dead Cell Double Staining
 746 kit 30 min before being imaged. Cells were washed with PBS to remove fluorophores in solution, non-internalized
 747 particles, and detached cells, and were imaged using confocal fluorescence microscopy at $\lambda_{\text{ex}} = 488$ nm and $\lambda_{\text{em}} =$
 748 520-560 nm (green), or $\lambda_{\text{ex}} = 600$ nm and $\lambda_{\text{em}} = 635$ -700 nm (red). In parallel, samples were observed
 749 in brightfield mode to detect cell membranes and microparticles, while reflectance-mode data was acquired in
 750 some samples for easier visualization of the microparticles, yielding an image with pixel size of $dx = dy = 0.072$
 751 μm . Non-fluorescent Calcein-AM (acetoxymethyl ester of calcein) is highly lipophilic and cell membrane
 752 permeable. Intracellular esterases then generate calcein in a viable cell emitting a strong green fluorescence (λ_{ex}
 753 490 nm, $\lambda_{\text{em}} 515$ nm).

754 The *cell viability* [%] was calculated using ImageJ by quantifying the fluorescence in the green channel. For that,
 755 two different approaches were followed. In the first approach, the *cell viability* [%] was estimated as shown in
 756 the equation:

757 *Eq. 1*

$$758 \quad \text{Cell viability total esterase activity}[\%] = \frac{FI_{\text{image}}(\text{sample})}{FI_{\text{image}}(\text{untreated})} \cdot 100$$

759 Where FI_{image} is the integrated fluorescence intensity of the images. According to this approach, values reflect the
 760 total esterase activity of the sample after treatment with particles, and is influenced by the number and size of
 761 cells (cell confluency) remaining in the sample, as well as by the esterase activity of each cell. Thus, this approach
 762 is equivalent to other conventional methods for assessing the cell viability in solution such as MTT.⁵⁹

763 In the second approach, areas of the image containing cells ($n \geq 10$) were delimited, and the mean fluorescence
 764 was quantified in such areas. Then, the *cell viability* [%] was then obtained as follows:

765 *Eq. 2*

$$766 \quad \text{Cell viability}_{\text{mean intracellular esterase activity}} [\%] = \frac{MFI_{\text{cells}}(\text{sample})}{MFI_{\text{cells}}(\text{untreated})} \cdot 100$$

767 Where MFI_{cells} is the mean fluorescence intensity of cells. According to this approach, values are not influenced by
 768 the number and size of cells remaining in the sample, but they specifically reflect the esterase activity within cells
 769 after treatment with particles. The comparison of *cell viability* values using both approaches could provide
 770 information about the number and size of cells after treatment.

771 Using both approaches (eq. 1 and 2), the *cytotoxicity per particle* [cell/**SiμP**] was calculated according to the
 772 equation:

773 Eq. 3

$$774 \quad \text{Cytotoxicity per particle} \left[\frac{\text{cell}}{\text{Si}\mu\text{P}} \right] = \left(\frac{100 - \text{Cell viability}}{100} \right) \left(\frac{n_{\text{cells}}}{n_{\text{Si}\mu\text{P}}} \right)$$

775 Where n_{cells} is the estimated number of cells in each well at the start of the experiment (ca. 100 000), and $n_{\text{Si}\mu\text{P}}$ is
 776 the total number of microparticles dosed to the cells. This proportion of cells to microparticles is also the inverse
 777 value of the **SiμP**:cells ratio [**SiμP**/cell].

778 Finally, the *cytotoxicity per bipy* [cell/bipy] was calculated as follows:

779 Eq. 4

$$780 \quad \text{Cytotoxicity per bipy} \left[\frac{\text{cell}}{\text{bipy}} \right] = \frac{\text{Cytotoxicity per particle}}{\text{bipy per particle}}$$

781 Where *bipy per particle* [bipy/**SiμP**] is the total number of bipyridinium moieties conjugated per particle,
 782 considering the number of molecules conjugated and the number of bipyridinium moieties contained in each
 783 molecule.

784 To observe the mechanism of cytotoxicity of the microparticles, Hela cells were incubated in DMEM at ≈80%
 785 confluency (≈476000 cells per well), and were treated with compound **1** solution at a final concentration of 100
 786 μM for 1, 2, 4, or 24 h, or with 10, 20, or 40 μL of a suspension of 97.6 **SiμP**/μL of **SiμP-1** (**SiμP**:cells 0.002:1,
 787 0.004:1, or 0.008:1) for 2, 4, or 24 h. 30 min prior observation, cells were washed and incubated with CellROX®
 788 orange, after which they were washed and observed using a Zeiss LSM 880 confocal fluorescence microscope.
 789 Samples were observed at λ_{ex} 561 nm and λ_{em} 566-759 nm (orange-red), λ_{ex} 405 nm and λ_{em} 410-471 nm (violet-
 790 blue), and brightfield. Z-projections of the stacks acquired were made using ImageJ yielding an image with pixel
 791 size $dx = dy = 0.208 \mu\text{m}$.

792 To observe more easily the membrane integrity loss, Hela cells were grown to ≈10 % confluency in 96-well plates
 793 (ca. 12,500 cells per well). PBS (40 μL) and DMEM (100 μL) was added, and a suspension of microparticles (40
 794 μL) in PBS was finally added. Cells were incubated for 24 h at 37°C and 5 % CO₂ for observing cells and their
 795 interaction with the microparticles. Samples were observed on a LionheartFX (BioTek) automated microscope
 796 with an Olympus 10X PL FL Phase objective. Images were acquired in brightfield mode yielding an image with
 797 pixel size $dx = dy = 0.658 \mu\text{m}$.

798 Acknowledgements

799 ERDF (FEDER) funds and Spanish government grants TEC2017-85059-C3-1 and 2-R, and PID2020-115663GB-
 800 C3-1 and 2 are acknowledged. D. Limón thanks Consortium for Advanced Studies Abroad (CASA) for a
 801 postdoctoral fellowship. J. F. Stoddart, K. Cai and Y. Beldjoudi thank Northwestern University for continuing
 802 support. Authors thank Manel Bosch from Scientific and Technological Centers of the University of Barcelona
 803 (CCITUB) for his kind support with cell cultures and microscopy experiments.

1
2
3
4
5
6
7
8
9

804 **Supporting Information Available**

805 Contact angle measurements of functionalized silicon wafers, XPS studies, functionalization of **Si μ P** with
806 bipyridinium compounds, confocal fluorescence microscopy images of **Si-3** wafers and of **Si μ P-3** microparticles,
807 particle count experiments, internalization in Hela cells, cytotoxicity quantification of functionalized
808 microparticles in Hela cells, and cytotoxic effects at low confluency.

10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

809 **Financial Interests**

810 Authors declare no financial interests.

811

812

813 **References**

- 814 (1) Fornari, F. A.; Randolph, J. K.; Yalowich, J. C.; Ritke, M. K.; Gewirtz, D. A. Interference by Doxorubicin with
815 DNA Unwinding in MCF-7 Breast Tumor Cells. *Mol. Pharmacol.* **1994**, *45* (4), 694–656.
- 816 (2) Rajagopalan, P. T. R.; Zhang, Z.; McCourt, L.; Dwyer, M.; Benkovic, S. J.; Hammes, G. G. Interaction of
817 Dihydrofolate Reductase with Methotrexate: Ensemble and Single-Molecule Kinetics. *Proc. Natl. Acad. Sci.*
818 *U. S. A.* **2002**, *99* (21), 13481–13486.
- 819 (3) Kollmannsberger, C.; Mross, K.; Jakob, A.; Kanz, L.; Bokemeyer, C. Topotecan – A Novel Topoisomerase I
820 Inhibitor: Pharmacology and Clinical Experience. *Oncology* **1999**, *56* (1), 1–12.
- 821 (4) Roskoski, R. A Historical Overview of Protein Kinases and Their Targeted Small Molecule Inhibitors.
822 *Pharmacol. Res.* **2015**, *100*, 1–23.
- 823 (5) Jordan, M. A.; Wilson, L. Microtubules As a Target for Anticancer Drugs. *Nat. Rev. Cancer* **2004**, *4* (April),
824 253–265.
- 825 (6) Oun, R.; Moussa, Y. E.; Wheate, N. J. The Side Effects of Platinum-Based Chemotherapy Drugs: A Review
826 for Chemists. *Dalt. Trans.* **2018**, *47* (19), 6645–6653.
- 827 (7) Frank, M.; Hennenberg, E. M.; Eyking, A.; Rünzi, M.; Gerken, G.; Scott, P.; Parkhill, J.; Walker, A. W.; Cario,
828 E. TLR Signaling Modulates Side Effects of Anticancer Therapy in the Small Intestine. *J. Immunol.* **2015**,
829 *194* (4), 1983–1995.
- 830 (8) Russo, S.; Cinausero, M.; Gerratana, L.; Bozza, C.; Iacono, D.; Driol, P.; Deroma, L.; Sottile, R.; Fasola, G.;
831 Puglisi, F. Factors Affecting Patient’s Perception of Anticancer Treatments Side-Effects: An Observational
832 Study. *Expert Opin. Drug Saf.* **2014**, *13* (2), 139–150.
- 833 (9) Accordino, M. K.; Neugut, A. I.; Hershman, D. L. Cardiac Effects of Anticancer Therapy in the Elderly. *J.*
834 *Clin. Oncol.* **2014**, *32* (24), 2654–2661.
- 835 (10) Hohenforst-Schmidt, W.; Zarogoulidis, P.; Darwiche, K.; Vogl, T.; Goldberg, E. P.; Huang, H.; Simoff, M.;
836 Li, Q.; Browning, R.; Turner, F. J.; et al. Intratumoral Chemotherapy for Lung Cancer: Re-Challenge
837 Current Targeted Therapies. *Drug Des. Devel. Ther.* **2013**, *7*, 571–583.
- 838 (11) Fang, J.; Nakamura, H.; Maeda, H. The EPR Effect: Unique Features of Tumor Blood Vessels for Drug
839 Delivery, Factors Involved, and Limitations and Augmentation of the Effect. *Adv. Drug Deliv. Rev.* **2011**, *63*
840 (3), 136–151.
- 841 (12) Iyer, A. K.; Khaled, G.; Fang, J.; Maeda, H. Exploiting the Enhanced Permeability and Retention Effect for
842 Tumor Targeting. *Drug Discov. Today* **2006**, *11* (17–18), 812–818.
- 843 (13) Ding, Y.; Xu, Y.; Yang, W.; Niu, P.; Li, X.; Chen, Y.; Li, Z.; Liu, Y.; An, Y.; Liu, Y.; et al. Investigating the EPR
844 Effect of Nanomedicines in Human Renal Tumors via Ex Vivo Perfusion Strategy. *Nano Today* **2020**, *35*,
845 100970.
- 846 (14) Yan, L.; Shen, J.; Wang, J.; Yang, X.; Dong, S.; Lu, S. Nanoparticle-Based Drug Delivery System: A Patient-
847 Friendly Chemotherapy for Oncology. *Dose-Response* **2020**, *18* (3), 1–12.
- 848 (15) Valente, K. P.; Suleman, A.; Brolo, A. G. Exploring Diffusion and Cellular Uptake: Charged Gold
849 Nanoparticles in an in Vitro Breast Cancer Model. *ACS Appl. Bio Mater.* **2020**, *3* (10), 6992–7002.
- 850 (16) Dai, Q.; Wilhelm, S.; Ding, D.; Syed, A. M.; Sindhwani, S.; Zhang, Y.; Chen, Y. Y.; Macmillan, P.; Chan, W.

- 1
2
3 851 C. W. Quantifying the Ligand-Coated Nanoparticle Delivery to Cancer Cells in Solid Tumors. *ACS Nano*
4 852 **2018**, *12* (8), 8423–8435.
- 6 853 (17) Park, K. Questions on the Role of the EPR Effect in Tumor Targeting. *J. Control. Release* **2013**, *172* (1), 391.
- 8 854 (18) Cruickshank Miller, C. The Stokes-Einstein Law for Diffusion in Solution. *Proc. R. Soc. A. Math. Phys. Eng.*
9 855 *Sci.* **1924**, *106* (740), 724–749.
- 10 856 (19) Peulen, T. O.; Wilkinson, K. J. Diffusion of Nanoparticles in a Biofilm. *Environ. Sci. Technol.* **2011**, *45* (8),
11 857 3367–3373.
- 13 858 (20) Shi, W.; Wang, J.; Fan, X.; Gao, H. Size and Shape Effects on Diffusion and Absorption of Colloidal Particles
14 859 near a Partially Absorbing Sphere: Implications for Uptake of Nanoparticles in Animal Cells. *Phys. Rev. E*
15 860 *- Stat. Nonlinear, Soft Matter Phys.* **2008**, *78* (6), 1–11.
- 17 861 (21) Habimana, O.; Steenkeste, K.; Fontaine-Aupart, M. P.; Bellon-Fontaine, M. N.; Kulakauskas, S.; Briandet,
18 862 R. Diffusion of Nanoparticles in Biofilms Is Altered by Bacterial Cell Wall Hydrophobicity. *Appl. Environ.*
19 863 *Microbiol.* **2011**, *77* (1), 367–368.
- 21 864 (22) Kim, B.; Han, G.; Toley, B. J.; Kim, C. K.; Rotello, V. M.; Forbes, N. S. Tuning Payload Delivery in Tumour
22 865 Cylindroids Using Gold Nanoparticles. *Nat. Nanotechnol.* **2010**, *5* (6), 465–472.
- 24 866 (23) Cho, E. C.; Zhang, Q.; Xia, Y. The Effect of Sedimentation and Diffusion on Cellular Uptake of Gold
25 867 Nanoparticles. *Nat. Nanotechnol.* **2011**, *6* (6), 385–391.
- 26 868 (24) Safwat, M. A.; Soliman, G. M.; Sayed, D.; Attia, M. A. Fluorouracil-Loaded Gold Nanoparticles for the
27 869 Treatment of Skin Cancer: Development, in Vitro Characterization, and in Vivo Evaluation in a Mouse Skin
28 870 Cancer Xenograft Model. *Mol. Pharm.* **2018**, *15* (6), 2194–2205.
- 30 871 (25) Sonavane, G.; Tomoda, K.; Sano, A.; Ohshima, H.; Terada, H.; Makino, K. In Vitro Permeation of Gold
31 872 Nanoparticles through Rat Skin and Rat Intestine: Effect of Particle Size. *Colloids Surfaces B Biointerfaces*
32 873 **2008**, *65* (1), 1–10.
- 34 874 (26) Larese Filon, F.; Crosera, M.; Adami, G.; Bovenzi, M.; Rossi, F.; Maina, G. Human Skin Penetration of Gold
35 875 Nanoparticles through Intact and Damaged Skin. *Nanotoxicology* **2011**, *5* (4), 493–501.
- 37 876 (27) Gupta, R.; Rai, B. Effect of Size and Surface Charge of Gold Nanoparticles on Their Skin Permeability: A
38 877 Molecular Dynamics Study. *Sci. Rep.* **2017**, *7* (October 2016), 1–13.
- 40 878 (28) Lerche, D. Comprehensive Characterization of Nano- and Microparticles by in-Situ Visualization of Particle
41 879 Movement Using Advanced Sedimentation Techniques. *KONA Powder Part. J.* **2019**, *36* (36), 156–186.
- 43 880 (29) Serda, R. E.; Gu, J.; Bhavane, R. C.; Liu, X. W.; Chiappini, C.; Decuzzi, P.; Ferrari, M. The Association of
44 881 Silicon Microparticles with Endothelial Cells in Drug Delivery to the Vasculature. *Biomaterials* **2009**, *30*
45 882 (13), 2440–2448.
- 47 883 (30) Salonen, J.; Laitinen, L.; Kaukonen, A. M.; Tuura, J.; Björkqvist, M.; Heikkilä, T.; Vähä-Heikkilä, K.;
48 884 Hirvonen, J.; Lehto, V. P. Mesoporous Silicon Microparticles for Oral Drug Delivery: Loading and Release
49 885 of Five Model Drugs. *J. Control. Release* **2005**, *108* (2–3), 362–374.
- 51 886 (31) Haidary, S. M.; Córcoles, E. P.; Ali, N. K. Nanoporous Silicon as Drug Delivery Systems for Cancer
52 887 Therapies. *J. Nanomater.* **2012**, 2012.
- 53 888 (32) Anglin, E. J.; Cheng, L.; Freeman, W. R.; Sailor, M. J. Porous Silicon in Drug Delivery Devices and Materials.
54 889 *Adv. Drug Deliv. Rev.* **2008**, *60* (11), 1266–1277.

- 1
2
3 890 (33) Aguil, J. P.; Torras, N.; Duch, M.; Esteve, J.; Pérez-García, L.; Samitier, J.; Plaza, J. A. Highly Anisotropic
4 891 Suspended Planar-Array Chips with Multidimensional Sub-Micrometric Biomolecular Patterns. *Adv.*
5 892 *Funct. Mater.* **2017**, *27* (13).
- 7 893 (34) Torras, N.; Aguil, J. P.; Vázquez, P.; Duch, M.; Hernández-Pinto, A. M.; Samitier, J.; De La Rosa, E. J.;
8 894 Esteve, J.; Suárez, T.; Pérez-García, L.; et al. Suspended Planar-Array Chips for Molecular Multiplexing at
9 895 the Microscale. *Adv. Mater.* **2016**, *28* (7), 1449–1454.
- 11 896 (35) Novo, S.; Penon, O.; Barrios, L.; Nogués, C.; Santaló, J.; Durán, S.; Gómez-Matínez, R.; Samitier, J.; Plaza,
12 897 J. A.; Pérez-García, L.; et al. Direct Embryo Tagging and Identification System by Attachment of
13 898 Biofunctionalized Polysilicon Barcodes to the Zona Pellucida of Mouse Embryos. *Hum. Reprod.* **2013**, *28*
14 899 (6), 1519–1527.
- 16 900 (36) Penon, O.; Novo, S.; Druán, S.; Ibañez, E.; Nogués, C.; Samitier, J.; Duch, M.; Plaza, J. A.; Pérez-García, L.
17 901 Efficient Biofunctionalization of Polysilicon Barcodes for Adhesion to the Zona Pellucida of Mouse
18 902 Embryos. *Bioconjug. Chem.* **2012**, No. 23, 2392–2402.
- 20 903 (37) Fernández-Rosas, E.; Gómez, R.; Ibañez, E.; Barrios, L.; Duch, M.; Esteve, J.; Plaza, J. A.; Nogués, C.
21 904 Internalization and Cytotoxicity Analysis of Silicon-Based Microparticles in Macrophages and Embryos.
22 905 *Biomed. Microdevices* **2010**, *12* (3), 371–379.
- 24 906 (38) Alea-Reyes, M. E.; Rodrigues, M.; Serrà, A.; Mora, M.; Sagristá, M. L.; González, A.; Durán, S.; Duch, M.;
25 907 Plaza, J. A.; Vallés, E.; et al. Nanostructured Materials for Photodynamic Therapy: Synthesis,
26 908 Characterization and in Vitro Activity. *RSC Adv.* **2017**, *7* (28), 16963–16976.
- 28 909 (39) Durán, S.; Duch, M.; Patiño, T.; Torres, A.; Penon, O.; Gómez-Martínez, R.; Barrios, L.; Esteve, J.; Nogués,
29 910 C.; Pérez-García, L.; et al. Technological Development of Intracellular Polysilicon-Chromium-Gold Chips
30 911 for Orthogonal Chemical Functionalization. *Sensors Actuators, B Chem.* **2015**, *209*, 212–224.
- 32 912 (40) Fernández-Rosas, E.; Baldi, A.; Ibañez, E.; Barrios, L.; Novo, S.; Esteve, J.; Plaza, J. A.; Duch, M.; Gómez,
33 913 R.; Castell, O.; et al. Chemical Functionalization of Polysilicon Microparticles for Single-Cell Studies.
34 914 *Langmuir* **2011**, *27* (13), 8302–8308.
- 36 915 (41) Gómez-Martínez, R.; Vázquez, P.; Duch, M.; Muriano, A.; Pinacho, D.; Sanvicens, N.; Sánchez-Baeza, F.;
37 916 Boya, P.; De La Rosa, E. J.; Esteve, J.; et al. Intracellular Silicon Chips in Living Cells. *Small* **2010**, *6* (4),
38 917 499–502.
- 40 918 (42) Bruce, G.; Samperi, M.; Amabilino, D. B.; Duch, M.; Plaza, J. A.; Pérez-García, L. Singlet Oxygen Generation
41 919 from Porphyrin-Functionalized Hexahedral Polysilicon Microparticles. *J. Porphyr. Phthalocyanines* **2019**,
42 920 *23* (1–2), 223–233.
- 44 921 (43) Ashton, P. R.; Balzani, V.; Becher, J.; Credi, A.; Fyfe, M. C. T.; Mattersteig, G.; Menzer, S.; Nielsen, M. B.;
45 922 Raymo, F. M.; Stoddart, J. F.; et al. A Three-Pole Supramolecular Switch. *J. Am. Chem. Soc.* **1999**, *121* (16),
46 923 3951–3957.
- 48 924 (44) Cai, K.; Cui, B.; Song, B.; Wang, H.; Qiu, Y.; Jones, L. O.; Liu, W.; Shi, Y.; Vemuri, S.; Shen, D.; et al. Radical
49 925 Cyclic [3]Daisy Chains. *Chem* **2021**, *7* (1), 174–189.
- 51 926 (45) Liu, Y.; Flood, A. H.; Bonvallet, P. A.; Vignon, S. A.; Northrop, B. H.; Tseng, H. R.; Jeppesen, J. O.; Huang,
52 927 T. J.; Brough, B.; Baller, M.; et al. Linear Artificial Molecular Muscles. *J. Am. Chem. Soc.* **2005**, *127* (27),
53 928 9745–9759.
- 54 929 (46) Roy, I.; Goswami, S.; Young, R. M.; Schlesinger, I.; Mian, M. R.; Enciso, A. E.; Zhang, X.; Hornick, J. E.;
55 930 Farha, O. K.; Wasielewski, M. R.; et al. Photon Upconversion in a Glowing Metal-Organic Framework. *J.*

- 1
2
3 931 *Am. Chem. Soc.* **2021**, *143* (13), 5053–5059.
- 4
5 932 (47) Roy, I.; Bobbala, S.; Zhou, J.; Nguyen, M. T.; Nalluri, S. K. M.; Wu, Y.; Ferris, D. P.; Scott, E. A.; Wasielewski,
6 933 M. R.; Stoddart, J. F. ExTzBox: A Glowing Cyclophane for Live-Cell Imaging. *J. Am. Chem. Soc.* **2018**, *140*
7 934 (23), 7206–7212.
- 8
9 935 (48) Garci, A.; Beldjoudi, Y.; Kodaimati, M. S.; Hornick, J. E.; Nguyen, M. T.; Cetin, M. M.; Stern, C. L.; Roy, I.;
10 936 Weiss, E. A.; Stoddart, J. F. Mechanical-Bond-Induced Exciplex Fluorescence in an Anthracene-Based
11 937 Homo[2]Catenane. *J. Am. Chem. Soc.* **2020**, *142* (17), 7956–7967.
- 12
13 938 (49) Baer, K. N. Paraquat. *Encyclopedia of Toxicology (Second Edition)*; Elsevier, 2005; pp 329–330.
- 14
15 939 (50) Bus, J. S.; Aust, S. D.; Gibson, J. E. Paraquat Toxicity: Proposed Mechanism of Action Involving Lipid
16 940 Peroxidation. *Environ. Health Perspect.* **1976**, *16*, 139–146.
- 17
18 941 (51) Suntres, Z. E. Role of Antioxidants in Paraquat Toxicity. *Toxicology* **2002**, *180* (1), 65–77.
- 19
20 942 (52) Wang, S.; Wu, H.; Chen, F.; Zhang, Y.; Zhang, Y.; Sun, B. The Antitumor Activity of 4,4'-Bipyridinium
21 943 Amphiphiles. *RSC Adv.* **2019**, *9* (57), 33023–33028.
- 22
23 944 (53) Sheeney-Haj-Ichia, L.; Wasserman, J.; Willner, I. CdS-Nanoparticle Architectures on Electrodes for
24 945 Enhanced Photocurrent Generation. *Adv. Mater.* **2002**, *14* (18), 1323–1326.
- 25
26 946 (54) Liang, W.; Yi, W.; Li, S.; Yuan, R.; Chen, A.; Chen, S.; Xiang, G.; Hu, C. A Novel, Label-Free Immunosensor
27 947 for the Detection of α -Fetoprotein Using Functionalised Gold Nanoparticles. *Clin. Biochem.* **2009**, *42* (15),
28 948 1524–1530.
- 29
30 949 (55) Cheng, C. A.; Deng, T.; Lin, F. C.; Cai, Y.; Zink, J. I. Supramolecular Nanomachines as Stimuli-Responsive
31 950 Gatekeepers on Mesoporous Silica Nanoparticles for Antibiotic and Cancer Drug Delivery. *Theranostics*
32 951 **2019**, *9* (11), 3341–3364.
- 33
34 952 (56) Wen, J.; Yang, K.; Liu, F.; Li, H.; Xu, Y.; Sun, S. Diverse Gatekeepers for Mesoporous Silica Nanoparticle
35 953 Based Drug Delivery Systems. *Chem. Soc. Rev.* **2017**, *46* (19), 6024–6045.
- 36
37 954 (57) Flood, A. H.; Nygaard, S.; Laursen, B. W.; Jeppesen, J. O.; Stoddart, J. F. Locking down the Electronic
38 955 Structure of (Monopyrrolo)Tetrathiafulvalene in [2]Rotaxanes. *Org. Lett.* **2006**, *8* (11), 2205–2208.
- 39
40 956 (58) Amirthalingam, E. Multi-Functionalization of Micro- and Nanoparticles for Cancer Theranostics,
41 957 Universitat de Barcelona, 2018.
- 42
43 958 (59) Stockert, J. C.; Horobin, R. W.; Colombo, L. L.; Blázquez-Castro, A. Tetrazolium Salts and Formazan
44 959 Products in Cell Biology: Viability Assessment, Fluorescence Imaging, and Labeling Perspectives. *Acta*
45 960 *Histochem.* **2018**, *120* (3), 159–167.
- 46
47 961 (60) Ayala, A.; Muñoz, M. F.; Argüelles, S. Lipid Peroxidation: Production, Metabolism, and Signaling
48 962 Mechanisms of Malondialdehyde and 4-Hydroxy-2-Nonenal. *Oxid. Med. Cell. Longev.* **2014**, *2014*, 1–31.
- 49
50 963 (61) Farmer, E. E.; Mueller, M. J. ROS-Mediated Lipid Peroxidation and RES-Activated Signaling. *Annu. Rev.*
51 964 *Plant Biol.* **2013**, *64*, 429–450.
- 52
53 965 (62) Havaux, M.; Triantaphylidès, C.; Genty, B. Autoluminescence Imaging: A Non-Invasive Tool for Mapping
54 966 Oxidative Stress. *Trends Plant Sci.* **2006**, *11* (10), 480–484.
- 55
56 967 (63) Griess, B.; Tom, E.; Domann, F.; Teoh-Fitzgerald, M. Extracellular Superoxide Dismutase and Its Role in
57 968 Cancer. *Free Radic. Biol. Med.* **2017**, *112* (3), 464–479.
- 58
59 969 (64) Attri, P.; Kim, Y. H.; Park, D. H.; Park, J. H.; Hong, Y. J.; Uhm, H. S.; Kim, K. N.; Fridman, A.; Choi, E. H.

- 1
2
3 970 Generation Mechanism of Hydroxyl Radical Species and Its Lifetime Prediction during the Plasma-Initiated
4 971 Ultraviolet (UV) Photolysis. *Sci. Rep.* **2015**, *5*, 1–8.
- 5
6 972 (65) Croissant, J. G.; Brinker, C. J. *Biodegradable Silica-Based Nanoparticles: Dissolution Kinetics and Selective*
7 973 *Bond Cleavage*, 1st ed.; Elsevier Inc., 2018; Vol. 43.
- 8
9 974 (66) Lin, Y.-K.; Huang, Z.-R.; Zhuo, R.-Z.; Fang, J.-Y. Combination of Calcipotriol and Methotrexate in
10 975 Nanostructured Lipid Carriers for Topical Delivery. *Int. J. Nanomedicine* **2010**, *5*, 117–128.
- 11 976 (67) Olson, M. A.; Coskun, A.; Klajn, R.; Fang, L.; Dey, S. K.; Browne, K. P.; Grzybowski, B. A.; Stoddart, J. F.
12 977 Assembly of Polygonal Nanoparticle Clusters Directed by Reversible Noncovalent Bonding Interactions.
13 978 *Nano Lett.* **2009**, *9* (9), 3185–3190.
- 14
15 979 (68) Wu, Y.; Zhou, J.; Phelan, B. T.; Mauck, C. M.; Stoddart, J. F.; Young, R. M.; Wasielewski, M. R. Probing
16 980 Distance Dependent Charge-Transfer Character in Excimers of Extended Viologen Cyclophanes Using
17 981 Femtosecond Vibrational Spectroscopy. **2017**.
- 18
19 982
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60